{"altmetric_id":20391756,"counts":{"readers":{"mendeley":45,"citeulike":0,"connotea":0},"total":{"posts_count":231},"news":{"unique_users_count":73,"unique_users":["eurekalert","newsmax_com","48_waff","the_new_england_journal_of_medicine","ticker_tech","benzinga","abc_7_news_kswo","fox_14_news","kusi_news","news_channel","kait_tv","wlox","wrcb_tv","kten","nbc_right_now_kndu_25","wtvm","azfamily_com","kplc_7_news","klkn_tv_eyewitness_news","nbc12","kltv","cleveland_19","newson6","14_news","ksla_news_12","walb","mississippi_news_now","wtoc","wand_17","hawaii_news_now","wave_3_news","ktre","2_news","wmc_action_news_5","wdam_tv","wboc_16","cbs8","wflx_fox_29","south_carolina_news_now","wsfa","khq","wdrb","wfmj","kuam","news_channel_6","newswest9","wistv","wtol","kfve_the_home_team","wmbf_news","news_9","physicians_briefing","doctors_lounge","bloomberg","american_pharmacists_association","deutsches_arzteblatt","chicago_tribune","medscape","yahoo_news","the_medical_news","science_newsline","yahoo_finance_usa","new_york_times","business_insider","latest_nigerian_news","healthline","daily_mail","channel_newsasia","health_medicinet","science_daily","newswise","2_minute_medicine","my_news_desk"],"posts_count":83},"blogs":{"unique_users_count":1,"unique_users":[369],"posts_count":1},"twitter":{"unique_users_count":110,"unique_users":["sergiobarbaecua","ethanjweiss","wonkinakilt","westr","Carlacortezr","Aller_MD","wheezemd","pulmones","ATS_AII","manasigh","rikrdQF","LSainz_V","CarlaEisenstein","JeremyFarrar","PharmacyJoe","Bahena1970","GangFighterKy2","indusimm","ARIAGuideline","FUNDACIONLIBRA","Interasma","SocLatAlergia","SammyG_MD","rudmoha","martinrafco","induspulmon","weitelei","Erik_G_Anderson","Pharma_Mty","pontepedrat","drsmparker","PATCH_CNRS","jvalverde64","alergologos","SpaceMedic","NocciolaHR","animesh1977","franj_garcia","pedrojmarcos","_medjournal","asthma_papers","AstraZenecaUS","Innoplexus","KhouryMD","markcl208041","BruderStapleton","Prescriberight","DesanctisJuan","karadag68","tomheston","itziarlarrodele","youareinformed","AURELIN15","FarmaciaOesteAP","docalergias","JMDallergy","RevistaSOCAMPAR","afsb2013","LeoUzych","NottinghamRRU","drarequena","DoctorBarcelo","Bmestar","Martapc75","Marta_Palop","air_garcia","PLMcCarthyMD","ATS_BSHSR","LuisZuritaG","iBiznezz","juanjbosch","dilshad_moosa","NEJM","monitor_PH","dccc_phd","THebertMcGill","SOLTMANY","lee_jasonk","CardioLearn","ClinicalBriefs","kdahal57","KeprosSparrow","YNHallak","jaygeorge60","banavarrete","pulmonology101","SenectusSAS","mamylona1","YorkNHSLibrary","juancaz17","ichi1matsu","s_yeverino","Saramirzaei","JoseMartinConde","bibliotecaemcs","qgorgas","Kidedoc","MMJoseA1","AHC_Nurses","AHC_Doctors","AmerHealthCoun","danirossmm","LungOmics","TKTarrant","winder_gill","atscommunity","pirinoes","negrita73bn","PasqualiniDario","kawauso_srmsrnm"],"posts_count":128},"facebook":{"unique_users_count":13,"unique_users":["151167761740441","92777318461","490570534304779","353040794755369","1771340156523108","753349978012049","247598615295951","184810514976747","205360136242904","1475061309405514","107118352655018","411144645664454","130767083627618"],"posts_count":16},"wikipedia":{"unique_users_count":1,"unique_users":["en:26799209"],"posts_count":1},"googleplus":{"unique_users_count":2,"unique_users":["Juan Carlos Ivancevich","American Health Council"],"posts_count":2}},"selected_quotes":["#Asthma: benralizumab achieves steroid-sparing endpoint","Full Phase III results from ZONDA trial published in the New England Journal of Medicine #ATS2017","Latest P. Nair NEJM RCT: Benralizumab reduces prednisone dose by 75%, eliminates 1 exac'n per year in sev. asthma","Love the endpoint of reducing another toxic drug. Think same trial design can be used for insulin sparing","Benralizumab in Severe #asthma"],"citation":{"abstract":"Background Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia. Methods In a 28-week randomized, controlled trial, we assessed the effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or every 8 weeks [with the first three doses administered every 4 weeks]) versus placebo on the reduction in the oral glucocorticoid dose while asthma control was maintained in adult patients with severe asthma. The primary end point was the percentage change in the oral glucocorticoid dose from baseline to week 28. Annual asthma exacerbation rates, lung function, symptoms, and safety were assessed. Results Of 369 patients enrolled, 220 underwent randomization and started receiving benralizumab or placebo. The two benralizumab dosing regimens significantly reduced the median final oral glucocorticoid doses from baseline by 75%, as compared with a reduction of 25% in the oral glucocorticoid doses in the placebo group (P<0.001 for both comparisons). The odds of a reduction in the oral glucocorticoid dose were more than 4 times as high with benralizumab as with placebo. Among the secondary outcomes, benralizumab administered every 4 weeks resulted in an annual exacerbation rate that was 55% lower than the rate with placebo (marginal rate, 0.83 vs. 1.83, P=0.003), and benralizumab administered every 8 weeks resulted in an annual exacerbation rate that was 70% lower than the rate with placebo (marginal rate, 0.54 vs. 1.83, P<0.001). At 28 weeks, there was no significant effect of either benralizumab regimen on the forced expiratory volume in 1 second (FEV1), as compared with placebo. The effects on various measures of asthma symptoms were mixed, with some showing significant changes in favor of benralizumab and others not showing significant changes. Frequencies of adverse events were similar between each benralizumab group and the placebo group. Conclusions Benralizumab showed significant, clinically relevant benefits, as compared with placebo, on oral glucocorticoid use and exacerbation rates. These effects occurred without a sustained effect on the FEV1. (Funded by AstraZeneca; ZONDA ClinicalTrials.gov number, NCT02075255 .).","altmetric_jid":"4f6fa50e3cf058f6100031c4","authors":["Nair, Parameswaran","Wenzel, Sally","Rabe, Klaus F.","Bourdin, Arnaud","Lugogo, Njira L.","Kuna, Piotr","Barker, Peter","Sproule, Stephanie","Ponnarambil, Sandhia","Goldman, Mitchell","Rabe, Klaus F","Lugogo, Njira L",", ","Parameswaran Nair","Sally Wenzel","Klaus F. Rabe","Arnaud Bourdin","Njira L. Lugogo","Piotr Kuna","Peter Barker","Stephanie Sproule","Sandhia Ponnarambil","Mitchell Goldman"],"doi":"10.1056\/nejmoa1703501","first_seen_on":"2017-05-22T19:49:25+00:00","funders":["niehs"],"handles":[],"issns":["0028-4793","1533-4406"],"journal":"New England Journal of Medicine","last_mentioned_on":1505658820,"links":["http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF#.WSNAc2HP_SQ.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF#.WSNCI19DW_k.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF&utm_content=buffer7ffe2&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF#.WSNEWa5rzik.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF&utm_content=bufferd8ca9&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer","http:\/\/dx.doi.org\/10.1056\/NEJMoa1703501","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?rss=searchAndBrowse","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF#.WSN9xhTT4tc.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF#.WSN_geAYMgY.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF#.WSPa0VYxHYE.linkedin","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?af=R&rss=currentIssue","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28530840?dopt=Abstract","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28530840?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501#.WSQ-sMITvKc.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF#.WSRemvBUtjc.linkedin","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501#t=article","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=featured_home#.WSStXQ1o0T8.facebook","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28530840?dopt=Abstract&utm_source=dlvr.it&utm_medium=facebook","http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1703501","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=OF&utm_content=buffer60255&utm_medium=social&utm_source=linkedin.com&utm_campaign=buffer","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?utm_content=buffer6617f&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?utm_content=buffer4aa68&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501#.WSeAjNXQc2E.twitter","http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1703501","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?utm_content=buffer6617f&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer#.WSgpVdvBlVQ.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501#.WSyjNTsCM4U.linkedin","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501#.WTE3pd0tq4o.twitter","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28530840?utm_content=buffer1559b&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=allergy-immunology#.WTa3XkGvg8A.linkedin","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=allergy-immunology#.WTbMZbsRNBE.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=pulmonary","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=TOC","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501#.WUweZlkJYPc.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=featured_home","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=featured_home&","https:\/\/www.ncbi.nlm.nih.gov\/m\/pubmed\/28530840\/","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501#.WV2TxaclWsQ.twitter","http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?platform=hootsuite"],"pmid":"28530840","pubdate":"2017-05-23T10:38:18+00:00","publisher":"Massachusetts Medical Society","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["medicine"],"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/oral-glucocorticoidsparing-effect-benralizumab-severe-asthma"},"altmetric_score":{"score":647.7,"score_history":{"1y":647.7,"6m":647.7,"3m":19.8,"1m":7,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":647.7},"context_for_score":{"all":{"total_number_of_other_articles":8425604,"mean":7.0878923279354,"rank":4856,"this_scored_higher_than_pct":99,"this_scored_higher_than":8421047,"rank_type":"exact","sample_size":8425604,"percentile":99},"similar_age_3m":{"total_number_of_other_articles":244730,"mean":12.634668126785,"rank":410,"this_scored_higher_than_pct":99,"this_scored_higher_than":244320,"rank_type":"exact","sample_size":244730,"percentile":99},"this_journal":{"total_number_of_other_articles":20351,"mean":49.430533366093,"rank":241,"this_scored_higher_than_pct":98,"this_scored_higher_than":20110,"rank_type":"exact","sample_size":20351,"percentile":98},"similar_age_this_journal_3m":{"total_number_of_other_articles":297,"mean":240.96479054054,"rank":29,"this_scored_higher_than_pct":90,"this_scored_higher_than":268,"rank_type":"exact","sample_size":297,"percentile":90}}},"demographics":{"poster_types":{"member_of_the_public":77,"researcher":11,"practitioner":18,"science_communicator":4},"users":{"twitter":{"cohorts":{"Members of the public":77,"Scientists":11,"Practitioners (doctors, other healthcare professionals)":18,"Science communicators (journalists, bloggers, editors)":4}},"mendeley":{"by_status":{"Unspecified":2,"Professor > Associate Professor":2,"Librarian":1,"Student  > Doctoral Student":3,"Researcher":7,"Student  > Ph. D. Student":2,"Student  > Postgraduate":2,"Other":16,"Student  > Master":1,"Student  > Bachelor":4,"Lecturer":1,"Lecturer > Senior Lecturer":1,"Professor":3},"by_discipline":{"Engineering":1,"Medicine and Dentistry":34,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":4,"Nursing and Health Professions":1,"Unspecified":3,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"EC":2,"US":26,"AR":1,"MX":4,"GB":1,"CA":4,"VE":2,"TW":1,"SE":1,"FR":1,"ES":10,"KR":1,"NO":1,"TR":1,"BA":1,"CO":3,"BR":1,"GD":1,"IT":1,"JP":2,"AU":1,"PA":1},"mendeley":{"US":2,"MX":1,"TN":1}}},"posts":{"news":[{"title":"New medicine shows potential to reduce oral steroid use in severe asthma patients","url":"http:\/\/ct.moreover.com\/?a=30691953706&p=1pl&v=1&x=UBgDjQng16VkKlsZC5QPHA","license":"public","citation_ids":[20391756],"posted_on":"2017-05-25T04:00:00+00:00","summary":"Hamilton, ON (May 25, 2017) - A trial led by a McMaster University respirology professor shows promising results for a new medicine for severe asthma patients.","author":{"name":"EurekAlert!","url":"http:\/\/www.eurekalert.org\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/077\/normal\/image.png?1369859505"}},{"title":"New Asthma Drug Slashes Steroid Use","url":"http:\/\/ct.moreover.com\/?a=30664631371&p=1pl&v=1&x=7M9K0tC2RLp9ZFOLYZYibg","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T12:39:47+00:00","summary":"AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.","author":{"name":"newsmax.com","url":"http:\/\/www.newsmax.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/354\/normal\/Screen_Shot_2015-04-07_at_17.01.46.png?1428422529"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663970605&p=1pl&v=1&x=uhhKFPWmJxmPjtV2ntQmaw","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"48 WAFF","url":"http:\/\/www.waff.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/699\/normal\/Screen_Shot_2016-01-26_at_14.47.41.png?1453819680"}},{"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma","url":"http:\/\/ct.moreover.com\/?a=30657655566&p=1pl&v=1&x=6HihjUKCssbKEy4qQO8WTw","license":"public","citation_ids":[20391155,20391756],"posted_on":"2017-05-22T00:00:00+00:00","summary":"Editor's Note: The narration and closed captions in this video are in English. For subtitles in 13 other languages, see this video on the website of the World Health Organization.","author":{"name":"The New England Journal of Medicine ","url":"http:\/\/www.nejm.org\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/541\/normal\/Screen_Shot_2016-01-06_at_16.20.23.png?1452097246"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663733780&p=1pl&v=1&x=WJJHID3QeBACF2AnMyWYAQ","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:07:45+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations requiring emergency room visits or\u2026","author":{"name":"Ticker Tech","url":"http:\/\/www.tickertech.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/724\/normal\/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663762734&p=1pl&v=1&x=mk6Kcb_0iTZ3u9jmX-vVng","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:10:41+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations requiring emergency room visits or\u2026","author":{"name":"Benzinga","url":"http:\/\/www.benzinga.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/738\/normal\/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663876505&p=1pl&v=1&x=LzYqwAA4Nt1eBywA5M2oYw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:22:20+00:00","summary":"Information contained on this page is provided by an independent third-party content provider.","author":{"name":"ABC 7 News KSWO","url":"http:\/\/www.kswo.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/708\/normal\/Screen_Shot_2016-01-26_at_15.08.58.png?1453821021"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663881858&p=1pl&v=1&x=Qjgfg1wybBz7wyulTOTJdg","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"Fox 14 News","url":"http:\/\/www.fox14tv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/651\/normal\/Screen_Shot_2016-01-26_at_12.00.07.png?1453809650"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663897859&p=1pl&v=1&x=5kaR3N5oZllvhDqslAcRPA","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:24:44+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"KUSI News","url":"http:\/\/www.kusi.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/663\/normal\/Screen_Shot_2016-01-26_at_13.26.05.png?1453815145"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663901357&p=1pl&v=1&x=ioJxDEL_rGRnsaHA-2J4rg","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"News Channel","url":"http:\/\/www.kxxv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/645\/normal\/Screen_Shot_2016-01-26_at_11.42.27.png?1453808595"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663900526&p=1pl&v=1&x=NtH3ZaqwOZDy3tUczOpSKw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:25:01+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"KAIT-TV","url":"http:\/\/www.kait8.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/672\/normal\/Screen_Shot_2016-01-26_at_14.02.53.png?1453817085"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663908957&p=1pl&v=1&x=C7hvd_ceVPkcJX3vuRPs9g","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"WLOX","url":"http:\/\/www.wlox.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/657\/normal\/Screen_Shot_2016-01-26_at_12.08.48.png?1453810156"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663909555&p=1pl&v=1&x=HrW_f2KwvFhkI2tmqnXU5w","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:26:01+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WRCB- TV","url":"http:\/\/www.wrcbtv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/690\/normal\/Screen_Shot_2016-01-26_at_14.32.42.png?1453818828"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663915828&p=1pl&v=1&x=ZJKGeYd1Fkvw4A5snW0WmA","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:26:43+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"KTEN","url":"http:\/\/www.kten.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/643\/normal\/Screen_Shot_2016-01-26_at_11.36.58.png?1453808251"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663924723&p=1pl&v=1&x=TiI8sNa2R6W47McgRo1tnw","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"NBC Right Now KNDU 25","url":"http:\/\/www.nbcrightnow.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/735\/normal\/Screen_Shot_2016-01-26_at_15.54.16.png?1453823699"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663932450&p=1pl&v=1&x=z7SlYEzfL6c0BiWVoh2-Rw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:28:31+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WTVM","url":"http:\/\/www.wtvm.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/646\/normal\/Screen_Shot_2016-02-02_at_14.58.13.png?1454425111"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663939087&p=1pl&v=1&x=uhoM0OL-2FW5uxY-UIY3MQ","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:29:15+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"azfamily.com","url":"http:\/\/azfamily.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/500\/normal\/Screen_Shot_2016-01-12_at_14.25.15.png?1452608728"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663942706&p=1pl&v=1&x=lALG-Oxh__Mbu9KRRv4Vzg","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"KPLC 7 News","url":"http:\/\/www.kplctv.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/641\/normal\/Screen_Shot_2016-01-26_at_11.30.17.png?1453807834"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663944420&p=1pl&v=1&x=nxDNRc1icva3yCCCs12wMA","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"KLKN-TV Eyewitness News","url":"http:\/\/www.klkntv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/655\/normal\/Screen_Shot_2016-01-26_at_12.06.08.png?1453810028"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663948534&p=1pl&v=1&x=ZhBiUtIyJyqi-N-JxtK62w","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:30:19+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"NBC12","url":"http:\/\/www.nbc12.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/702\/normal\/Screen_Shot_2016-01-26_at_14.51.21.png?1453819926"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663949969&p=1pl&v=1&x=kH1XfGmmEbS1DIN9MD2Ozw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:30:28+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"KLTV","url":"http:\/\/www.kltv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/704\/normal\/Screen_Shot_2016-01-26_at_14.54.15.png?1453820113"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663963207&p=1pl&v=1&x=pf1VzvQTDIGpejIUXUEZVA","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:31:43+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"Cleveland 19","url":"http:\/\/www.cleveland19.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/683\/normal\/Screen_Shot_2016-01-26_at_14.20.50.png?1453818081"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663969459&p=1pl&v=1&x=WDyrdcUga4zDn-ds6SFdiQ","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:32:28+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"NewsOn6","url":"http:\/\/www.newson6.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/677\/normal\/Screen_Shot_2016-01-26_at_14.12.15.png?1453817572"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663978689&p=1pl&v=1&x=0u1-4uvJw0bJukdc_Jstng","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:33:28+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"14 News","url":"http:\/\/www.14news.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/696\/normal\/Screen_Shot_2016-01-26_at_14.43.50.png?1453819462"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663980788&p=1pl&v=1&x=70MAL7YkPbeuK9t3dpHn9A","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:33:42+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"KSLA News 12","url":"http:\/\/www.ksla.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/709\/normal\/Screen_Shot_2016-01-26_at_15.10.50.png?1453821079"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663990597&p=1pl&v=1&x=BiIiWlqQyKGFV2xNOLcrHQ","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"WALB","url":"http:\/\/www.walb.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/647\/normal\/Screen_Shot_2016-01-26_at_11.47.02.png?1453808851"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663992700&p=1pl&v=1&x=QW4JhY8RYCUWfQU7jJUZPw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:35:00+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"Mississippi News Now ","url":"http:\/\/www.msnewsnow.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/649\/normal\/Screen_Shot_2016-01-26_at_11.57.00.png?1453809440"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663992655&p=1pl&v=1&x=VvUBzNWkZ63UHnD6mVwezA","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:35:00+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WTOC","url":"http:\/\/www.wtoc.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/688\/normal\/Screen_Shot_2016-01-26_at_14.30.16.png?1453818642"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663995664&p=1pl&v=1&x=qcj60m6DRWWu1RvxZoq0Dw","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"WAND 17","url":"http:\/\/www.wandtv.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/694\/normal\/Screen_Shot_2016-01-26_at_14.41.02.png?1453819294"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30663997395&p=1pl&v=1&x=OBLwi9jJ9QZnTP8jMLO8-Q","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"Hawaii News Now","url":"http:\/\/www.hawaiinewsnow.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/661\/normal\/Screen_Shot_2016-01-26_at_12.16.42.png?1453810633"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664002348&p=1pl&v=1&x=jMc8WjohQbX6HrLpJTEULA","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"Wave 3 News","url":"http:\/\/www.wave3.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/697\/normal\/Screen_Shot_2016-01-26_at_14.44.55.png?1453819521"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664004091&p=1pl&v=1&x=gnh3NOhxAD8CnGu-tAL-zw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:36:13+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"KTRE","url":"http:\/\/www.ktre.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/705\/normal\/Screen_Shot_2016-01-26_at_15.04.21.png?1453820750"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664019098&p=1pl&v=1&x=56EZ-4RK80oUvGC3Vey5UQ","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:37:39+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"2 News","url":"http:\/\/www.ktvn.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/654\/normal\/Screen_Shot_2016-01-26_at_12.05.19.png?1453809947"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664021347&p=1pl&v=1&x=Vm4OvY6F_oEXryeWZbxVgg","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:37:57+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WMC Action News 5","url":"http:\/\/www.wmcactionnews5.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/727\/normal\/Screen_Shot_2016-01-26_at_15.42.23.png?1453822987"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664032891&p=1pl&v=1&x=rS23fztJhYn53J8TT71LTQ","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:39:07+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WDAM - TV","url":"http:\/\/www.wdam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/682\/normal\/Screen_Shot_2016-01-26_at_14.19.46.png?1453818016"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664036687&p=1pl&v=1&x=JeBoJTqBRqTbJ7oTLjTKeQ","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:39:32+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WBOC 16","url":"http:\/\/www.wboc.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/717\/normal\/Screen_Shot_2016-01-26_at_15.23.21.png?1453821908"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664037212&p=1pl&v=1&x=jNffvz0WQ6aMfELTJNEHyQ","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:39:35+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"CBS8","url":"http:\/\/www.cbs8.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/681\/normal\/Screen_Shot_2016-01-26_at_14.17.19.png?1453817863"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664046384&p=1pl&v=1&x=CAkEMTdIpp9E-Gjb0Ywm6A","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"WFLX Fox 29","url":"http:\/\/www.wflx.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/656\/normal\/Screen_Shot_2016-01-26_at_12.07.36.png?1453810094"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664049859&p=1pl&v=1&x=pVBlu9bnCZ_pwLQBHy8aYg","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:40:54+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"South Carolina News Now","url":"http:\/\/www.live5news.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/730\/normal\/Screen_Shot_2016-01-26_at_15.47.02.png?1453823263"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664055491&p=1pl&v=1&x=M2JkbVCYM4fMDcaMYIKKWg","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"WSFA ","url":"http:\/\/www.wsfa.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/644\/normal\/Screen_Shot_2016-01-26_at_11.40.39.png?1453808470"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664044315&p=1pl&v=1&x=0fQP0DSBK_Age8NNXljJjA","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:40:23+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"KHQ","url":"http:\/\/www.khq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/658\/normal\/Screen_Shot_2016-01-26_at_12.10.14.png?1453810239"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664075619&p=1pl&v=1&x=3gNnTQ9m2ghLqXspAQcZww","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:43:46+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WDRB","url":"http:\/\/www.wdrb.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/693\/normal\/Screen_Shot_2016-01-26_at_14.37.05.png?1453819066"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664079563&p=1pl&v=1&x=Z-FOnzP4kuXBRDavDyQAPg","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:44:13+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WFMJ","url":"http:\/\/www.wfmj.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/701\/normal\/Screen_Shot_2016-01-26_at_14.49.34.png?1453819812"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664086693&p=1pl&v=1&x=YpZlVGe6xuUcoDxFvtFKuw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:44:58+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"Kuam","url":"http:\/\/www.kuam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/667\/normal\/Screen_Shot_2016-01-26_at_13.48.34.png?1453816300"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664086821&p=1pl&v=1&x=8XSeIO6APm06UBG4Xf2_Uw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:44:59+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"News Channel 6","url":"http:\/\/www.newschannel6now.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/652\/normal\/Screen_Shot_2016-01-26_at_12.01.23.png?1453809711"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664092759&p=1pl&v=1&x=2Jvf3x_2kJ-wlhV_3aYG9g","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:45:36+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"NewsWest9","url":"http:\/\/www.newswest9.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/703\/normal\/Screen_Shot_2016-01-26_at_14.52.45.png?1453820009"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664093918&p=1pl&v=1&x=fy7NZ5F89zYWwpYwhLpV1Q","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"WISTV","url":"http:\/\/www.wistv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/689\/normal\/Screen_Shot_2016-01-26_at_14.30.56.png?1453818748"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664103430&p=1pl&v=1&x=xy0JRTJUvuf4Inoa51cSpw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:46:44+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WTOL","url":"http:\/\/www.wtol.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/662\/normal\/Screen_Shot_2016-01-26_at_12.19.14.png?1453810785"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664066530&p=1pl&v=1&x=uqAXGCh-eqyRog1QHAyw2w","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T11:21:00+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1.","author":{"name":"KFVE The Home Team","url":"http:\/\/www.k5thehometeam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/734\/normal\/Screen_Shot_2016-01-26_at_15.53.15.png?1453823633"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664132439&p=1pl&v=1&x=mpQ5I7GAq2hWnFkhbnxAZQ","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:49:55+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"WMBF News","url":"http:\/\/www.wmbfnews.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/710\/normal\/Screen_Shot_2016-01-26_at_15.11.39.png?1453821128"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664152479&p=1pl&v=1&x=zbvN2aBFJqpcfY7aFpPxPw","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:51:55+00:00","summary":"SOURCE AstraZeneca Canada Inc. Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo1 Benralizumab also reduced overall exacerbation rates by 70%2 and exacerbations\u2026","author":{"name":"News 9","url":"http:\/\/www.news9.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/691\/normal\/Screen_Shot_2016-01-26_at_14.34.55.png?1453818924"}},{"title":"Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30664266861&p=1pl&v=1&x=TyAzGDJfowt0woMqCcz19g","license":"public","citation_ids":[20391756,20391756],"posted_on":"2017-05-23T11:00:35+00:00","summary":"Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo 1 Benralizumab also reduced overall exacerbation rates by 70% 2 and exacerbations requiring emergency room visits\u2026","author":{"name":"Benzinga","url":"http:\/\/www.benzinga.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/738\/normal\/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}},{"title":"ATS: Benralizumab Reduces Glucocorticoid Doses in Asthma","url":"http:\/\/ct.moreover.com\/?a=30666988885&p=1pl&v=1&x=Z2werYFOHK-qMLfscg4xWA","license":"public","citation_ids":[20391756,20391756,20391756],"posted_on":"2017-05-23T16:27:36+00:00","summary":"(HealthDay News) -- Benralizumab is associated with a significant reduction in glucocorticoid doses among adults with severe asthma, according to a study published online May 22 in the New England Journal of Medicine.","author":{"name":"Physician's Briefing","url":"http:\/\/www.physiciansbriefing.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/372\/normal\/logo.png?1436525474"}},{"title":"ATS: Benralizumab Reduces Glucocorticoid Doses in Asthma","url":"http:\/\/ct.moreover.com\/?a=30668066944&p=1pl&v=1&x=PH6VSMqLGFLS3SHQSdu77w","license":"public","citation_ids":[20391756,20391756,20391756],"posted_on":"2017-05-23T18:21:01+00:00","summary":"Category: Internal Medicine | Allergy | Emergency Medicine | Pharmacy | Pulmonology | Conference News Benralizumab is associated with a significant reduction in glucocorticoid doses among adults with severe asthma, according to a study published\u2026","author":{"name":"Doctors Lounge","url":"http:\/\/www.doctorslounge.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/301\/normal\/Screen_Shot_2016-02-02_at_15.39.07.png?1454427565"}},{"title":"Cannabis Drug Halved Convulsions in Company-Funded Epilepsy Test","url":"http:\/\/ct.moreover.com\/?a=30685606998&p=1pl&v=1&x=i4wwnDY9NpPqn7qYt9x1HQ","license":"public","citation_ids":[4685161,20391756,4596779],"posted_on":"2017-05-25T06:42:51+00:00","summary":"GW Pharmaceuticals\u2019 Epidiolex shown to help in Dravet Syndrome Company plans new drug application filing with FDA in mid 2017 A cannabis-based drug halved the frequency of convulsive seizures in sufferers of a rare, catastrophic form of epilepsy in\u2026","author":{"name":"Bloomberg","url":"http:\/\/www.bloomberg.com\/europe","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/659\/normal\/Screen_Shot_2016-01-26_at_12.11.18.png?1453810324"}},{"title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","url":"http:\/\/ct.moreover.com\/?a=30679912596&p=1pl&v=1&x=zxRdfWN7yTMN9_eCEGgpBQ","license":"public","citation_ids":[20391756],"posted_on":"2017-05-24T13:00:01+00:00","summary":"Researchers explored whether benralizumab, a monoclonal antibody that helps prevent asthma exacerbations, might also reduce the amount of oral glucocorticoid that severe asthmatics need to effectively manage their disease.","author":{"name":"American Pharmacists Association","url":"http:\/\/pharmacist.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/423\/normal\/Screen_Shot_2016-01-06_at_11.37.09.png?1452080276"}},{"title":"Asthma: Antikrper Benralizumab senkt Bedarf an systemischen... (25.05.2017)","url":"http:\/\/ct.moreover.com\/?a=30689730734&p=1pl&v=1&x=vub98-rq_MJYRNbynCqV3Q","license":"public","citation_ids":[20391756],"posted_on":"2017-05-25T14:28:00+00:00","summary":"Medizin Donnerstag, 25. Mai 2017 tussik stock.adobe.de Montreal Der Antikrper Benralizumab, der nach Bindung an der Alpha-Kette des Interleukin 5-Rezeptors eine nahezu komplette Vernichtung aller eosinophilen Granulozyten auslst, hat in einer\u2026","author":{"name":"Deutsches \u00c4rzteblatt","url":"http:\/\/www.aerzteblatt.de\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/970\/normal\/image.png?1403704977"}},{"title":"American Thoracic Society, May 19-24","url":"http:\/\/ct.moreover.com\/?a=30694011565&p=1pl&v=1&x=tVja5uQnPb9Eq0GocgITUw","license":"public","citation_ids":[20366926,20366926,20391756,20391756],"posted_on":"2017-05-25T23:05:05+00:00","summary":"The American Thoracic Society's 2017 International Conference The annual meeting of the American Thoracic Society was held from May 19 to 24 in Washington, D.C., and attracted more than 14,000 participants from around the world, including clinicians\u2026","author":{"name":"Physician's Briefing","url":"http:\/\/www.physiciansbriefing.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/372\/normal\/logo.png?1436525474"}},{"title":"American Thoracic Society, May 19-24","url":"http:\/\/ct.moreover.com\/?a=30694504230&p=1pl&v=1&x=nLEvfwPWCPKTO419meHYQQ","license":"public","citation_ids":[20366926,20366926,20391756,20391756],"posted_on":"2017-05-26T00:14:46+00:00","summary":"The annual meeting of the American Thoracic Society was held from May 19 to 24 in Washington, D.C., and attracted more than 14,000 participants from around the world, including clinicians, academicians, allied health professionals, and others\u2026","author":{"name":"Doctors Lounge","url":"http:\/\/www.doctorslounge.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/301\/normal\/Screen_Shot_2016-02-02_at_15.39.07.png?1454427565"}},{"title":"Cannabis drug reduced epileptic seizures in new study","url":"http:\/\/ct.moreover.com\/?a=30702058875&p=1pl&v=1&x=mJC-1lLGfGza34jZ4_lv1Q","license":"public","citation_ids":[4685161,20391756,4596779],"posted_on":"2017-05-26T14:21:00+00:00","summary":"A cannabis-based drug halved the frequency of convulsive seizures in sufferers of a rare, catastrophic form of epilepsy in a late-stage study funded by GW Pharmaceuticals.","author":{"name":"Chicago Tribune","url":"http:\/\/www.chicagotribune.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/010\/normal\/chicago_tribune.png?1369846898"}},{"title":"AstraZeneca's Severe Asthma Drug Shows Promise","url":"http:\/\/ct.moreover.com\/?a=30742980130&p=1pl&v=1&x=o8Yg7RsiphlVhFk8I_kjlg","license":"public","citation_ids":[20391756],"posted_on":"2017-05-30T19:17:32+00:00","summary":"LONDON (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later\u2026","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}},{"title":"Severe asthma drug shows AstraZeneca promise beyond cancer","url":"http:\/\/ct.moreover.com\/?a=30666798583&p=1pl&v=1&x=YXVAgTslBF3Z0ZR-Q1rlhA","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T18:42:01+00:00","summary":"More Thomson Reuters By Ben Hirschler LONDON (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that\u2026","author":{"name":"Yahoo! News","url":"http:\/\/news.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/032\/normal\/yahoo_news.png?1369846922"}},{"title":"Trial shows promising results for new medicine in treating severe asthma patients","url":"http:\/\/ct.moreover.com\/?a=30695756257&p=1pl&v=1&x=FW-yGkeuEILZbwhGFGTOTQ","license":"public","citation_ids":[20391756],"posted_on":"2017-05-26T02:16:19+00:00","summary":"A trial led by a McMaster University respirology professor shows promising results for a new medicine for severe asthma patients.","author":{"name":"The Medical News","url":"http:\/\/www.news-medical.net\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/146\/normal\/image.png?1369927508"}},{"title":"New Medicine Shows Potential to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30704782903&p=1pl&v=1&x=zTo3vmtCpL_RKFwgIASt2A","license":"public","citation_ids":[20391756],"posted_on":"2017-05-26T16:46:00+00:00","summary":") - A trial led by a respirology professor shows promising results for a new medicine for severe asthma patients.","author":{"name":"Science Newsline","url":"http:\/\/www.sciencenewsline.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/245\/normal\/Screen_Shot_2016-02-02_at_17.20.48.png?1454433662"}},{"title":"AstraZeneca asthma shot hits goal but diabetes drug lags rival","url":"http:\/\/ct.moreover.com\/?a=30662262569&p=1pl&v=1&x=v6jcSgqbKSY5r7qcYFosFA","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T08:33:39+00:00","summary":"By Ben Hirschler LONDON (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"AstraZeneca Asthma Shot Hits Goal but Diabetes Drug Lags Rival","url":"http:\/\/ct.moreover.com\/?a=30662270314&p=1pl&v=1&x=LwZc0icjBr7YjtumaHYCcw","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T08:27:27+00:00","summary":"LONDON \u2014 AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.","author":{"name":"New York Times","url":"http:\/\/www.nytimes.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/022\/normal\/image.png?1369859672"}},{"title":"AstraZeneca asthma shot hits goal but diabetes drug lags rival","url":"http:\/\/ct.moreover.com\/?a=30662343226&p=1pl&v=1&x=ciXpBjIC3TcnPXTUo9jXoQ","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T08:42:21+00:00","summary":"By Ben Hirschler LONDON (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"An experimental injection cut the need for people with severe asthma to take steroid pills","url":"http:\/\/ct.moreover.com\/?a=30668035753&p=1pl&v=1&x=3y_vjeQ9J6j-8V4F_k7PQA","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T18:11:00+00:00","summary":"LONDON (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later\u2026","author":{"name":"Business Insider","url":"http:\/\/www.businessinsider.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/271\/normal\/Screen_Shot_2016-01-06_at_15.23.25.png?1452093826"}},{"title":"An experimental injection cut the need for people with severe asthma to take steroid pills (AZN)","url":"http:\/\/ct.moreover.com\/?a=30668398020&p=1pl&v=1&x=VW66FM-xGff47nCLRpzlHA","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T18:39:01+00:00","summary":"Published by Business Insider on Tue, 23 May 2017 LONDON (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a\u2026","author":{"name":"Latest Nigerian News","url":"http:\/\/www.latestnigeriannews.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/002\/350\/normal\/Screen_Shot_2016-03-15_at_16.54.15.png?1458060892"}},{"title":"Is It Time to Get Rid of Traditional Asthma Inhalers?","url":"http:\/\/ct.moreover.com\/?a=30805954408&p=1pl&v=1&x=VmkN1Gt5HssX8JZlS5PfTA","license":"public","citation_ids":[19770847,20391756],"posted_on":"2017-06-05T17:00:00+00:00","summary":"Millions of Americans live with asthma, a chronic lung disorder that can\u2019t be cured and can cause fatal attacks.","author":{"name":"Healthline ","url":"http:\/\/www.healthline.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/406\/normal\/Screen_Shot_2015-12-10_at_14.21.53.png?1449757426"}},{"title":"Benralizumab bei Asthma: Weniger Cortison, weniger Exazerbationen","url":"http:\/\/ct.moreover.com\/?a=30835461999&p=1pl&v=1&x=Z35-efB2iOv1E-ie3HRyzw","license":"public","citation_ids":[11744321,11744314,20391756],"posted_on":"2017-06-08T09:49:30+00:00","summary":"Washington, DC \u2013 Der Interleukin-5-Rezeptorantagonist Benralizumab kann bei schwerem eosinophilem Asthma im Vergleich zu Placebo die Dosis oraler Glukokortikoide und die Exazerbationsrate signifikant senken.","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}},{"title":"Severe asthma drug shows AstraZeneca promise beyond cancer","url":"http:\/\/ct.moreover.com\/?a=30655849634&p=1pl&v=1&x=PzPRiQVIzpzf1JNKD0jfPA","license":"nla","citation_ids":[20391756],"posted_on":"2017-05-22T18:34:03+00:00","summary":"Published: 19:34 BST, 22 May 2017 | Updated: 19:34 BST, 22 May 2017 By Ben Hirschler LONDON, May 22 (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in\u2026","author":{"name":"Daily Mail","url":"http:\/\/www.dailymail.co.uk","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/002\/normal\/image.png?1369859436"}},{"title":"Severe asthma drug shows AstraZeneca promise beyond cancer","url":"http:\/\/ct.moreover.com\/?a=30655880606&p=1pl&v=1&x=LsL20XisoDn47gtc9HJPig","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T18:38:29+00:00","summary":"By Ben Hirschler LONDON, May 22 (Reuters) - AstraZeneca (NYSE: AZN - news ) 's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"Severe asthma drug shows AstraZeneca promise beyond cancer","url":"http:\/\/ct.moreover.com\/?a=30655888308&p=1pl&v=1&x=ZKusihsXxTUWJMORzrtWzg","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T18:30:00+00:00","summary":"By Ben Hirschler LONDON, May 22 (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected\u2026","author":{"name":"Business Insider","url":"http:\/\/www.businessinsider.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/271\/normal\/Screen_Shot_2016-01-06_at_15.23.25.png?1452093826"}},{"title":"Severe asthma drug shows AstraZeneca promise beyond cancer","url":"http:\/\/ct.moreover.com\/?a=30656059830&p=1pl&v=1&x=B76EK7Bv5WDcKcqIpchwoQ","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T18:45:07+00:00","summary":"LONDON: AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.","author":{"name":"Channel NewsAsia","url":"http:\/\/www.channelnewsasia.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/527\/normal\/Screen_Shot_2016-01-12_at_14.40.15.png?1452609632"}},{"title":"Severe asthma drug shows AstraZeneca promise beyond cancer","url":"http:\/\/ct.moreover.com\/?a=30657895661&p=1pl&v=1&x=UNay2c8I6flHPvGJ5BT9_w","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T22:07:11+00:00","summary":"\/ no comments LONDON AstraZeneca\u2019s experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market\u2026","author":{"name":"Health Medicinet","url":"http:\/\/healthmedicinet.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/942\/normal\/image.png?1402915110"}},{"title":"Investigational biologic may reduce need for systemic corticosteroids in patients with severe asthma","url":"http:\/\/ct.moreover.com\/?a=30659594848&p=1pl&v=1&x=iDsK201ZQ8hUson0rKlEaA","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T02:40:32+00:00","summary":"An investigational biologic may reduce the need for adults with severe asthma to take an oral corticosteroid to control their asthma, according to a randomized controlled trial presented at the ATS 2017 International Conference.","author":{"name":"The Medical News","url":"http:\/\/www.news-medical.net\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/146\/normal\/image.png?1369927508"}},{"title":"Investigational biologic appears to reduce oral corticosteroid use in severe asthma","url":"http:\/\/ct.moreover.com\/?a=30661137190&p=1pl&v=1&x=Yd-JjaJs9zncYyRs2vEQjQ","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T06:07:37+00:00","summary":"An investigational biologic may reduce the need for adults with severe asthma to take an oral corticosteroid to control their asthma, according to a randomized controlled trial presented at the ATS 2017 International Conference.","author":{"name":"Health Medicinet","url":"http:\/\/healthmedicinet.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/942\/normal\/image.png?1402915110"}},{"title":"Investigational biologic appears to reduce oral corticosteroid use in severe asthma","url":"http:\/\/ct.moreover.com\/?a=30680898914&p=1pl&v=1&x=_gs5p0v0dWyQz2aj3fhZmA","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T12:35:54+00:00","summary":"An investigational biologic may reduce the need for adults with severe asthma to take an oral corticosteroid to control their asthma, according to a randomized controlled trial presented at the ATS 2017 International Conference.","author":{"name":"Science Daily","url":"http:\/\/www.sciencedaily.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/179\/normal\/image.png?1369927053"}},{"title":"New Medicine Shows Potential to Reduce Oral Steroid Use in Severe Asthma Patients","url":"http:\/\/ct.moreover.com\/?a=30692526204&p=1pl&v=1&x=irGAm2dbE5Q3XF6puvZlXw","license":"public","citation_ids":[20391756],"posted_on":"2017-05-25T19:05:33+00:00","summary":"Return to Article List Article ID: 675391 Released: 25-May-2017 2:05 PM EDT Source Newsroom: McMaster University Add to Favorites more news from this source Share MEDIA CONTACT Available for logged-in reporters only CHANNELS Asthma, Pharmaceuticals \u2026","author":{"name":"Newswise","url":"http:\/\/www.newswise.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/200\/normal\/image.png?1370251547"}},{"title":"New medicine shows potential to reduce oral steroid use in severe asthma patients","url":"http:\/\/ct.moreover.com\/?a=30693756684&p=1pl&v=1&x=xenCVtZRA6LZYRzNl7Mm3A","license":"public","citation_ids":[20391756],"posted_on":"2017-05-25T22:10:15+00:00","summary":"\/ no comments Hamilton, ON (May 25, 2017) \u2013 A trial led by a McMaster University respirology professor shows promising results for a new medicine for severe asthma patients.","author":{"name":"Health Medicinet","url":"http:\/\/healthmedicinet.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/942\/normal\/image.png?1402915110"}},{"title":"Benralizumab reduces oral steroid use in severe asthmatic patients | 2 Minute Medicine","url":"http:\/\/ct.moreover.com\/?a=31058414109&p=1pl&v=1&x=agtQ6lhugZcFAhfPzRxXVQ","license":"public","citation_ids":[20391756,481091],"posted_on":"2017-06-30T04:01:52+00:00","summary":"1. Use of the interleukin-5 receptor antibody benralizumab lowered oral glucocorticoid use while maintaining symptomatic control in patients with severe asthma on chronic oral glucocorticoids.","author":{"name":"2 Minute Medicine ","url":"http:\/\/www.2minutemedicine.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/278\/normal\/Screen_Shot_2014-11-20_at_11.49.13.png?1416484181"}},{"title":"Astrazeneca presents new results identifying severe asthma patients who would benefit most from Benralizumab","url":"http:\/\/ct.moreover.com\/?a=31797771685&p=1pl&v=1&x=KJXcGxtYGqxgjP3mEVDcrg","license":"public","citation_ids":[25097465,11744314,11744321,20391756],"posted_on":"2017-09-11T08:11:55+00:00","summary":"Further analysis of the Phase III trials, SIROCCO and CALIMA, reinforces benralizumab\u2019s efficacy and identifies more frequent prior exacerbations and\/or greater baseline blood eosinophil count as key predictors of an enhanced treatment effect\u2026","author":{"name":"My News Desk","url":"http:\/\/www.mynewsdesk.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/847\/normal\/Screen_Shot_2016-01-27_at_11.32.34.png?1453894453"}}],"facebook":[{"title":"Original Article: Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma http:\/\/nej.md\/2pSQapi  #ATS2017pic.twitter.com\/dLGpGiGc79","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=647779605412585&id=151167761740441","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T19:20:22+00:00","summary":"Original Article: Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma http:\/\/nej.md\/2pSQapi  #ATS2017 pic.twitter.com\/dLGpGiGc79","author":{"name":"Asociaci\u00f3n Colombiana de Medicina Interna","url":"https:\/\/www.facebook.com\/151167761740441","facebook_wall_name":"Asociaci\u00f3n Colombiana de Medicina Interna","image":"https:\/\/graph.facebook.com\/151167761740441\/picture","id_on_source":"151167761740441"}},{"title":"Photos from The New England Journal of Medicine's post","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=10154910334898462&id=92777318461","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T18:35:00+00:00","summary":"The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who re","author":{"name":"The New England Journal of Medicine","url":"https:\/\/www.facebook.com\/92777318461","facebook_wall_name":"The New England Journal of Medicine","image":"https:\/\/graph.facebook.com\/92777318461\/picture","id_on_source":"92777318461"}},{"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 NEJM","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1700705099957977&id=490570534304779","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T20:18:54+00:00","summary":"CONCLUSIONS\n\nBenralizumab showed significant, clinically relevant benefits, as compared with placebo, on oral glucocorticoid use and exacerbation rates. These effects occurred without a sustained effect on the FEV1. (Funded by AstraZeneca; ZONDA ClinicalTr","author":{"name":"Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI)","url":"https:\/\/www.facebook.com\/490570534304779","facebook_wall_name":"Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI)","image":"https:\/\/graph.facebook.com\/490570534304779\/picture","id_on_source":"490570534304779"}},{"title":"The New England Journal of Medicine","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1441640312562073&id=353040794755369","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T04:08:21+00:00","summary":"The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who re","author":{"name":"Clinical Cases for Discussion","url":"https:\/\/www.facebook.com\/353040794755369","facebook_wall_name":"Clinical Cases for Discussion","image":"https:\/\/graph.facebook.com\/353040794755369\/picture","id_on_source":"353040794755369"}},{"title":"The New England Journal of Medicine","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1854572408199882&id=1771340156523108","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T00:00:54+00:00","summary":"The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who re","author":{"name":"praktice.ai","url":"https:\/\/www.facebook.com\/1771340156523108","facebook_wall_name":"praktice.ai","image":"https:\/\/graph.facebook.com\/1771340156523108\/picture","id_on_source":"1771340156523108"}},{"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 NEJM","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1674521495894888&id=753349978012049","license":"public","citation_ids":[20391756],"posted_on":"2017-05-23T21:45:15+00:00","summary":"Original Article from The New England Journal of Medicine \u2014 Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma","author":{"name":"Revista Americana de Medicina Respiratoria","url":"https:\/\/www.facebook.com\/753349978012049","facebook_wall_name":"Revista Americana de Medicina Respiratoria","image":"https:\/\/graph.facebook.com\/753349978012049\/picture","id_on_source":"753349978012049"}},{"title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1346764488712686&id=247598615295951","license":"public","citation_ids":[20391756],"posted_on":"2017-05-24T07:05:37+00:00","summary":"Related Articles\n\nOral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. \n\nN Engl J Med. 2017 May 22;: \n\nAuthors: Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M, ZONDA Trial Investigator","author":{"name":"Tom Heston MD","url":"https:\/\/www.facebook.com\/247598615295951","facebook_wall_name":"Tom Heston MD","image":"https:\/\/graph.facebook.com\/247598615295951\/picture","id_on_source":"247598615295951"}},{"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 NEJM","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=515360431921752&id=184810514976747","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T20:10:57+00:00","summary":"Retweeted NEJM (@NEJM):\n\nOriginal Article: Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma https:\/\/t.co\/hb1w3qczB5 #ATS2017 https:\/\/t.co\/dLGpGiGc79","author":{"name":"ATS AII Assembly","url":"https:\/\/www.facebook.com\/184810514976747","facebook_wall_name":"ATS AII Assembly","image":"https:\/\/graph.facebook.com\/184810514976747\/picture","id_on_source":"184810514976747"}},{"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 NEJM","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1198970580215183&id=205360136242904","license":"public","citation_ids":[20391756],"posted_on":"2017-05-24T18:42:27+00:00","summary":"Exacerbation rate reduced by up to 70%\n\nA Phase III trial of benralizumab has shown the drug\u2019s ability to reduce oral corticosteroid use in severe asthma patients.  \n\nThe trial was lead by AllerGen investigator Dr. Parameswaran Nair.","author":{"name":"AllerGen Students and New Professionals Network (ASNPN)","url":"https:\/\/www.facebook.com\/205360136242904","facebook_wall_name":"AllerGen Students and New Professionals Network (ASNPN)","image":"https:\/\/graph.facebook.com\/205360136242904\/picture","id_on_source":"205360136242904"}},{"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 NEJM","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1704237476271406&id=490570534304779","license":"public","citation_ids":[20391756],"posted_on":"2017-05-26T02:45:37+00:00","summary":"Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of","author":{"name":"Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI)","url":"https:\/\/www.facebook.com\/490570534304779","facebook_wall_name":"Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI)","image":"https:\/\/graph.facebook.com\/490570534304779\/picture","id_on_source":"490570534304779"}},{"title":"Timeline Photos","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1940385792873061&id=1475061309405514","license":"public","citation_ids":[20391756],"posted_on":"2017-05-27T19:18:31+00:00","summary":"Scientific Research - 2017 - (79):\nInvestigational biologic appears to reduce oral corticosteroid use in severe asthma - benralizumab.\n\n* The biologic, benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, that when delivered subcutaneously,","author":{"name":"Pharmacology - Medicine","url":"https:\/\/www.facebook.com\/1475061309405514","facebook_wall_name":"Pharmacology - Medicine","image":"https:\/\/graph.facebook.com\/1475061309405514\/picture","id_on_source":"1475061309405514"}},{"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 NEJM","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1555124281187744&id=107118352655018","license":"public","citation_ids":[20391756],"posted_on":"2017-06-07T06:27:36+00:00","summary":"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501?query=pulmonary","author":{"name":"Centre for Evidence-based Medicine","url":"https:\/\/www.facebook.com\/107118352655018","facebook_wall_name":"Centre for Evidence-based Medicine","image":"https:\/\/graph.facebook.com\/107118352655018\/picture","id_on_source":"107118352655018"}},{"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 NEJM","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1215134421932135&id=411144645664454","license":"public","citation_ids":[20391756],"posted_on":"2017-06-14T13:00:00+00:00","summary":"Research from McMaster University and St. Joseph's Healthcare Hamilton indicates that benralizumab can reduce the need for oral GCS:  http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501#t=article\n#WeTheBreath #asthma #LungNerd #respiratorytherapy","author":{"name":"Canadian Society of Respiratory Therapists","url":"https:\/\/www.facebook.com\/411144645664454","facebook_wall_name":"Canadian Society of Respiratory Therapists","image":"https:\/\/graph.facebook.com\/411144645664454\/picture","id_on_source":"411144645664454"}},{"title":"Original Article: Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma http:\/\/nej.md\/2pSQapi pic.twitter.com\/oLVrrcmvAI","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=661050660752146&id=151167761740441","license":"public","citation_ids":[20391756],"posted_on":"2017-06-21T22:11:47+00:00","summary":"Original Article: Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma http:\/\/nej.md\/2pSQapi  pic.twitter.com\/oLVrrcmvAI","author":{"name":"Asociaci\u00f3n Colombiana de Medicina Interna","url":"https:\/\/www.facebook.com\/151167761740441","facebook_wall_name":"Asociaci\u00f3n Colombiana de Medicina Interna","image":"https:\/\/graph.facebook.com\/151167761740441\/picture","id_on_source":"151167761740441"}},{"title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1383918224997312&id=247598615295951","license":"public","citation_ids":[20391756],"posted_on":"2017-07-01T23:29:03+00:00","summary":"Related Articles\n\nOral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. \n\nN Engl J Med. 2017 06 22;376(25):2448-2458 \n\nAuthors: Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M, ZONDA Tri","author":{"name":"Tom Heston MD","url":"https:\/\/www.facebook.com\/247598615295951","facebook_wall_name":"Tom Heston MD","image":"https:\/\/graph.facebook.com\/247598615295951\/picture","id_on_source":"247598615295951"}},{"title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1402372253133755&id=130767083627618","license":"public","citation_ids":[20391756],"posted_on":"2017-07-02T08:12:32+00:00","summary":"Related Articles\n\nOral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. \n\nN Engl J Med. 2017 06 22;376(25):2448-2458 \n\nAuthors: Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M, ZONDA Tri","author":{"name":"Internet Medical Association","url":"https:\/\/www.facebook.com\/130767083627618","facebook_wall_name":"Internet Medical Association","image":"https:\/\/graph.facebook.com\/130767083627618\/picture","id_on_source":"130767083627618"}}],"twitter":[{"url":"http:\/\/twitter.com\/sergiobarbaecua\/statuses\/867934728632102912","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-26T02:45:39+00:00","author":{"name":"Sergio Barba","url":"http:\/\/www.aaaalergia.com","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","id_on_source":"sergiobarbaecua","tweeter_id":"188846475","geo":{"lt":-0.22985,"ln":-78.52495,"country":"EC"},"followers":61},"tweet_id":"867934728632102912"},{"url":"http:\/\/twitter.com\/ethanjweiss\/statuses\/866742750879686656","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-22T19:49:09+00:00","author":{"name":"Ethan Weiss","url":"http:\/\/profiles.ucsf.edu\/ethan.weiss","image":"https:\/\/pbs.twimg.com\/profile_images\/580892062104453120\/1FMEiXVI_normal.jpg","description":"UCSF scientist (metabolism)\/cardiologist (prevention); 2 crazed girls, 1 amazing wife @PalmerWeiss, 1 neurotic dog; @sfgiants\/ @Ravens & bandwagon @Warriors fan","id_on_source":"ethanjweiss","tweeter_id":"95292805","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":5134},"tweet_id":"866742750879686656"},{"url":"http:\/\/twitter.com\/wonkinakilt\/statuses\/866743668065153026","license":"gnip","rt":["ethanjweiss"],"citation_ids":[20391756],"posted_on":"2017-05-22T19:52:48+00:00","author":{"name":"Joe Colucci","image":"https:\/\/pbs.twimg.com\/profile_images\/871942803042877440\/Ku2SkJrI_normal.jpg","description":"Med student, @lowninstitute alum. Interested in evidence-based medicine & policy, #FOAMed, EM, palliative care. Acrobat, kinda. Opinions are (at most) my own.","id_on_source":"wonkinakilt","tweeter_id":"346586015","geo":{"lt":42.35843,"ln":-71.05977,"country":"US"},"followers":965},"tweet_id":"866743668065153026"},{"url":"http:\/\/twitter.com\/westr\/statuses\/866744593433415683","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-22T19:56:29+00:00","author":{"name":"Robert West PhD","url":"https:\/\/www.linkedin.com\/profile\/preview?locale=en_US&trk=prof-0-sb-preview-primary-button","image":"https:\/\/pbs.twimg.com\/profile_images\/500040415697833989\/p8hvJ9_i_normal.jpeg","description":"Personalized Medicine evangelist #PM101. From benches to trenches of #Healthcare. SUNY emeritus prof, \u00fcber patient advocate #MedEd #Asthma #Chronicpain #CSFleak","id_on_source":"westr","tweeter_id":"14267832","geo":{"lt":43.04812,"ln":-76.14742,"country":"US"},"followers":20433},"tweet_id":"866744593433415683"},{"url":"http:\/\/twitter.com\/Carlacortezr\/statuses\/866744984275386369","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-22T19:58:02+00:00","author":{"name":"carla cortez","image":"https:\/\/pbs.twimg.com\/profile_images\/885151981391810561\/qPLXVso-_normal.jpg","description":"\u2764  Dra en formacion .. #una vida entregada a los demas #26","id_on_source":"Carlacortezr","tweeter_id":"2744717134","geo":{"lt":null,"ln":null},"followers":63},"tweet_id":"866744984275386369"},{"url":"http:\/\/twitter.com\/Aller_MD\/statuses\/866745579711365121","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-22T20:00:24+00:00","author":{"name":"Juan C Ivancevich MD","image":"https:\/\/pbs.twimg.com\/profile_images\/906525202787520514\/NdEfNrQI_normal.jpg","description":"Allergist - Twittering on #allergy, #asthma & #immunology. Associate Professor of Immunology, del Salvador University, WAO website Chief Editor","id_on_source":"Aller_MD","tweeter_id":"23184067","geo":{"lt":-34.61315,"ln":-58.37723,"country":"AR"},"followers":5432},"tweet_id":"866745579711365121"},{"url":"http:\/\/twitter.com\/wheezemd\/statuses\/866746668200448001","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-22T20:04:43+00:00","author":{"name":"Michael Blaiss, MD","image":"https:\/\/pbs.twimg.com\/profile_images\/756202019170443265\/0V42zMQP_normal.jpg","description":"Allergist, Executive Medical Director of the American College of Allergy, Asthma, and Immunology","id_on_source":"wheezemd","tweeter_id":"13557562","geo":{"lt":null,"ln":null},"followers":3496},"tweet_id":"866746668200448001"},{"url":"http:\/\/twitter.com\/pulmones\/statuses\/866746995263717376","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-22T20:06:01+00:00","author":{"name":"Roberto Garay-Cabada","url":"http:\/\/pulmonespediatria.blogspot.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/1453746006\/Jul_19_11_normal.jpg","description":"Pediatra, Pulmonologia Pedi\u00e1trica Hermosillo, Sonora Mexico","id_on_source":"pulmones","tweeter_id":"126782814","geo":{"lt":23,"ln":-102,"country":"MX"},"followers":872},"tweet_id":"866746995263717376"},{"url":"http:\/\/twitter.com\/ATS_AII\/statuses\/866748235108536320","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-22T20:10:57+00:00","author":{"name":"ATS AII","url":"http:\/\/www.thoracic.org\/assemblies\/aii\/index.php","image":"https:\/\/pbs.twimg.com\/profile_images\/818513545113509888\/hvEgZ-pB_normal.jpg","description":"Welcome to the American Thoracic Society's AII Assembly Twitter feed","id_on_source":"ATS_AII","tweeter_id":"1954658088","geo":{"lt":null,"ln":null},"followers":223},"tweet_id":"866748235108536320"},{"url":"http:\/\/twitter.com\/manasigh\/statuses\/866748938250006532","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-22T20:13:44+00:00","author":{"name":"Mana","image":"https:\/\/pbs.twimg.com\/profile_images\/643451195768508417\/pYMSRWMl_normal.jpg","id_on_source":"manasigh","tweeter_id":"473483410","geo":{"lt":null,"ln":null},"followers":209},"tweet_id":"866748938250006532"},{"url":"http:\/\/twitter.com\/sergiobarbaecua\/statuses\/866750248533864453","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-22T20:18:57+00:00","author":{"name":"Sergio Barba","url":"http:\/\/www.aaaalergia.com","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","id_on_source":"sergiobarbaecua","tweeter_id":"188846475","geo":{"lt":-0.22985,"ln":-78.52495,"country":"EC"},"followers":61},"tweet_id":"866750248533864453"},{"url":"http:\/\/twitter.com\/rikrdQF\/statuses\/866753744607817729","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-22T20:32:50+00:00","author":{"name":"Ricardo Martinez","image":"https:\/\/pbs.twimg.com\/profile_images\/896472990745014272\/59eIoMdl_normal.jpg","description":"Qu\u00edmico laboratorista y Licenciado en farmacia","id_on_source":"rikrdQF","tweeter_id":"2548670845","geo":{"lt":20.11697,"ln":-98.73329,"country":"MX"},"followers":154},"tweet_id":"866753744607817729"},{"url":"http:\/\/twitter.com\/LSainz_V\/statuses\/866757042714705920","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-22T20:45:57+00:00","author":{"name":"Luis Sainz","image":"https:\/\/pbs.twimg.com\/profile_images\/2687546371\/c665e9f3b2e3cd3180b8247cf38d1f41_normal.jpeg","id_on_source":"LSainz_V","tweeter_id":"491555198","geo":{"lt":null,"ln":null},"followers":104},"tweet_id":"866757042714705920"},{"url":"http:\/\/twitter.com\/CarlaEisenstein\/statuses\/866768304353968128","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-22T21:30:42+00:00","author":{"name":"Carla Eisenstein","image":"https:\/\/pbs.twimg.com\/profile_images\/858792980798349312\/NlbS9tId_normal.jpg","description":"Pharmacist and medical writer.","id_on_source":"CarlaEisenstein","tweeter_id":"1482249655","geo":{"lt":42.35843,"ln":-71.05977,"country":"US"},"followers":126},"tweet_id":"866768304353968128"},{"url":"http:\/\/twitter.com\/JeremyFarrar\/statuses\/866768834274971650","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-22T21:32:48+00:00","author":{"name":"Jeremy Farrar","url":"http:\/\/wellcome.ac.uk","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000533045855\/5174e72399a4ea077f328e190aec270f_normal.jpeg","description":"Director of the Wellcome Trust (@WellcomeTrust).","id_on_source":"JeremyFarrar","tweeter_id":"1489776218","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":9105},"tweet_id":"866768834274971650"},{"url":"http:\/\/twitter.com\/PharmacyJoe\/statuses\/866789181225390080","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-22T22:53:39+00:00","author":{"name":"Pharmacy Joe \ud83c\uddfa\ud83c\uddf8","url":"http:\/\/pharmacyjoe.com","image":"https:\/\/pbs.twimg.com\/profile_images\/876981539367735296\/rakuRYmw_normal.jpg","description":"Helping #hospital #pharmacists gain practical skills and knowledge in the field of #criticalcare #pharmacy at http:\/\/pharmacyjoe.com | Supporter of #FOAMed","id_on_source":"PharmacyJoe","tweeter_id":"1357494109","geo":{"lt":null,"ln":null},"followers":7213},"tweet_id":"866789181225390080"},{"url":"http:\/\/twitter.com\/Bahena1970\/statuses\/866792016608456705","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-22T23:04:55+00:00","author":{"name":"Ra\u00fal Bahena","image":"https:\/\/pbs.twimg.com\/profile_images\/823997173465567236\/0nQq8jTt_normal.jpg","description":"M\u00e9dico Pediatra","id_on_source":"Bahena1970","tweeter_id":"864053012","geo":{"lt":null,"ln":null},"followers":76},"tweet_id":"866792016608456705"},{"url":"http:\/\/twitter.com\/GangFighterKy2\/statuses\/866800456999215104","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-22T23:38:27+00:00","author":{"name":"\u30e8\u30c3\u30b7\u30fc","image":"https:\/\/pbs.twimg.com\/profile_images\/716999221375709184\/YYOpmYfx_normal.jpg","description":"MD, Basic Researcher & Artist","id_on_source":"GangFighterKy2","tweeter_id":"714431915965571072","geo":{"lt":null,"ln":null},"followers":78},"tweet_id":"866800456999215104"},{"url":"http:\/\/twitter.com\/indusimm\/statuses\/866806413905063936","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T00:02:08+00:00","author":{"name":"Dr.Raj on Immunology","url":"http:\/\/bit.ly\/carlorajmd","image":"https:\/\/pbs.twimg.com\/profile_images\/707036458276818946\/JTA1WvX8_normal.jpg","description":"Facilitating the latest in #Immunology & #Allergy news for our growing #MedicalEducation community.  #MedEd #USMLE  Moderated by @CarloRajMD","id_on_source":"indusimm","tweeter_id":"3043327283","geo":{"lt":26.35869,"ln":-80.0831,"country":"US"},"followers":797},"tweet_id":"866806413905063936"},{"url":"http:\/\/twitter.com\/ARIAGuideline\/statuses\/866808934908260354","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-23T00:12:09+00:00","author":{"name":"ARIAguideline","url":"http:\/\/www.euforea.eu\/aria.html","image":"https:\/\/pbs.twimg.com\/profile_images\/879696169118683136\/oxS9M72d_normal.jpg","description":"The ARIA (Allergic Rhinitis and its Impact on Asthma) initiative aims to educate and implement evidence-based management of allergic rhinitis and asthma","id_on_source":"ARIAGuideline","tweeter_id":"367561906","geo":{"lt":null,"ln":null},"followers":1351},"tweet_id":"866808934908260354"},{"url":"http:\/\/twitter.com\/FUNDACIONLIBRA\/statuses\/866809065338490881","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-23T00:12:40+00:00","author":{"name":"Fundaci\u00f3n Libra","url":"http:\/\/www.fundacionlibra.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1130674087\/logo_normal.jpg","description":"Fundaci\u00f3n LIBRA (Fundaci\u00f3n Lucha Integral contra la Broncopat\u00eda, la Rinitis y el Asma)","id_on_source":"FUNDACIONLIBRA","tweeter_id":"194818089","geo":{"lt":null,"ln":null},"followers":359},"tweet_id":"866809065338490881"},{"url":"http:\/\/twitter.com\/Interasma\/statuses\/866809301498777601","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-23T00:13:36+00:00","author":{"name":"Interasma","url":"http:\/\/www.interasma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/481070665450016770\/o6EbOA8x_normal.jpeg","description":"Interasma is an international health organization focused on all aspects of asthma which bridges the gap between academia and the world of clinical practice.","id_on_source":"Interasma","tweeter_id":"147594153","geo":{"lt":null,"ln":null},"followers":1580},"tweet_id":"866809301498777601"},{"url":"http:\/\/twitter.com\/SocLatAlergia\/statuses\/866809374546821124","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-23T00:13:54+00:00","author":{"name":"SLaai","url":"http:\/\/www.slaai.org","image":"https:\/\/pbs.twimg.com\/profile_images\/469173940116393986\/4DtHZNic_normal.png","description":"Sociedad Latinoamericana de Alergia, Asma e Inmunolog\u00eda","id_on_source":"SocLatAlergia","tweeter_id":"367878837","geo":{"lt":null,"ln":null},"followers":1252},"tweet_id":"866809374546821124"},{"url":"http:\/\/twitter.com\/SammyG_MD\/statuses\/866809385879838721","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T00:13:56+00:00","author":{"name":"Samir Gupta","image":"https:\/\/pbs.twimg.com\/profile_images\/571752494141669376\/_FsrjaHG_normal.jpeg","description":"Physician (respirologist), Clinical Researcher in Knowledge Translation, eHealth, and Rare Lung Diseases, and Television Medical Correspondent","id_on_source":"SammyG_MD","tweeter_id":"594288484","geo":{"lt":43.70011,"ln":-79.4163,"country":"CA"},"followers":558},"tweet_id":"866809385879838721"},{"url":"http:\/\/twitter.com\/rudmoha\/statuses\/866810185666449408","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T00:17:07+00:00","author":{"name":"Ruda Mohaweche","image":"https:\/\/pbs.twimg.com\/profile_images\/906989975576748033\/MTYdC7lw_normal.jpg","id_on_source":"rudmoha","tweeter_id":"115247179","geo":{"lt":10.48801,"ln":-66.87919,"country":"VE"},"followers":113},"tweet_id":"866810185666449408"},{"url":"http:\/\/twitter.com\/martinrafco\/statuses\/866820493428576257","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-23T00:58:05+00:00","author":{"name":"Martin Correa","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000723541756\/cfc2d95ee97474491e46578948293c38_normal.jpeg","id_on_source":"martinrafco","tweeter_id":"2176175740","geo":{"lt":null,"ln":null},"followers":56},"tweet_id":"866820493428576257"},{"url":"http:\/\/twitter.com\/induspulmon\/statuses\/866821761639337986","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T01:03:07+00:00","author":{"name":"Dr.Raj: CriticalCare","url":"http:\/\/bit.ly\/carlorajmd","image":"https:\/\/pbs.twimg.com\/profile_images\/707060127438753793\/W6Pd1cE5_normal.jpg","description":"Facilitating the latest in #pulmonary & #criticalcare for our growing #MedEdcommunity. #USMLE\nCurated & Moderated by @CarloRajMD.","id_on_source":"induspulmon","tweeter_id":"705515439082774530","geo":{"lt":26.35869,"ln":-80.0831,"country":"US"},"followers":974},"tweet_id":"866821761639337986"},{"url":"http:\/\/twitter.com\/weitelei\/statuses\/866829954813542400","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-23T01:35:40+00:00","author":{"name":"\u96f7\u5049\u5fb7","image":"https:\/\/pbs.twimg.com\/profile_images\/703996213679423488\/j8JJrMbZ_normal.jpg","description":"Wei-Te Lei, MD, Pediatric Immunologist","id_on_source":"weitelei","tweeter_id":"703993882611023872","geo":{"lt":24,"ln":121,"country":"TW"},"followers":26},"tweet_id":"866829954813542400"},{"url":"http:\/\/twitter.com\/Erik_G_Anderson\/statuses\/866875615491837953","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-23T04:37:07+00:00","author":{"name":"Erik Andersson","image":"https:\/\/pbs.twimg.com\/profile_images\/613771681694384128\/maoGDgzJ_normal.jpg","description":"M.D.","id_on_source":"Erik_G_Anderson","tweeter_id":"1037739427","geo":{"lt":63.82842,"ln":20.25972,"country":"SE"},"followers":16},"tweet_id":"866875615491837953"},{"url":"http:\/\/twitter.com\/Pharma_Mty\/statuses\/866889507249029120","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-23T05:32:19+00:00","author":{"name":"Jose Hernandez","image":"https:\/\/pbs.twimg.com\/profile_images\/3738713976\/d12e3133940b643bdcdf549ca5dc915f_normal.jpeg","id_on_source":"Pharma_Mty","tweeter_id":"594887988","geo":{"lt":null,"ln":null},"followers":72},"tweet_id":"866889507249029120"},{"url":"http:\/\/twitter.com\/pontepedrat\/statuses\/866893377761140737","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T05:47:42+00:00","author":{"name":"H\u00e9ctor R Verea","image":"https:\/\/pbs.twimg.com\/profile_images\/810085704353087488\/1hPkPmI0_normal.jpg","description":"Pneumologist worried about the mankind\u2019s health. Passionate on Anthropology, lover of outdoors life, enviroment defender, reducing, reusing and recycling.","id_on_source":"pontepedrat","tweeter_id":"2872323892","geo":{"lt":null,"ln":null},"followers":165},"tweet_id":"866893377761140737"},{"url":"http:\/\/twitter.com\/drsmparker\/statuses\/866898547190484992","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-23T06:08:14+00:00","author":{"name":"sean parker","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","id_on_source":"drsmparker","tweeter_id":"2339175896","geo":{"lt":null,"ln":null},"followers":41},"tweet_id":"866898547190484992"},{"url":"http:\/\/twitter.com\/PATCH_CNRS\/statuses\/866904237351084033","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T06:30:51+00:00","author":{"name":"PATCH team","url":"http:\/\/gicc.cnrs.univ-tours.fr","image":"https:\/\/pbs.twimg.com\/profile_images\/850268315771486209\/cNkT81g6_normal.jpg","description":"\"Pharmacology of Therapeutic Antibodies in Human\" team of CNRS UMR 7292 (GICC) studies the relationship between dose and effects of mAbs","id_on_source":"PATCH_CNRS","tweeter_id":"849924490423304192","geo":{"lt":47.38333,"ln":0.68333,"country":"FR"},"followers":36},"tweet_id":"866904237351084033"},{"url":"http:\/\/twitter.com\/jvalverde64\/statuses\/866908256563810305","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T06:46:49+00:00","author":{"name":"Jos\u00e9 Valverde-Molina","url":"https:\/\/www.researchgate.net\/profile\/Jose_Valverde-Molina2","image":"https:\/\/pbs.twimg.com\/profile_images\/688447568813146122\/irDhuNWn_normal.jpg","description":"Pediatra Neum\u00f3logo. Jefe de Secci\u00f3n de Pediatr\u00eda. Hospital Universitario los Arcos del Mar Menor.\nPresidente de la SPSE","id_on_source":"jvalverde64","tweeter_id":"1055305087","geo":{"lt":38,"ln":-1.5,"country":"ES"},"followers":704},"tweet_id":"866908256563810305"},{"url":"http:\/\/twitter.com\/alergologos\/statuses\/866913443139530755","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T07:07:25+00:00","author":{"name":"Alergiayasma","url":"http:\/\/www.alergiayasma.es","image":"https:\/\/pbs.twimg.com\/profile_images\/439087675291611136\/-vfBAAzB_normal.jpeg","description":"Alergia y Asma Andaluc\u00eda","id_on_source":"alergologos","tweeter_id":"2222214355","geo":{"lt":null,"ln":null},"followers":1571},"tweet_id":"866913443139530755"},{"url":"http:\/\/twitter.com\/SpaceMedic\/statuses\/866927482175410177","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T08:03:13+00:00","author":{"name":"Space Medic","url":"http:\/\/instagram.com\/spacemedic","image":"https:\/\/pbs.twimg.com\/profile_images\/687232876354519041\/_anQGs4V_normal.jpg","description":"Space, medical and military news by @KrtNthny","id_on_source":"SpaceMedic","tweeter_id":"2289040586","geo":{"lt":37.56826,"ln":126.97783,"country":"KR"},"followers":541},"tweet_id":"866927482175410177"},{"url":"http:\/\/twitter.com\/NocciolaHR\/statuses\/866934811373469697","license":"gnip","rt":["alergologos"],"citation_ids":[20391756],"posted_on":"2017-05-23T08:32:20+00:00","author":{"name":"Hilda Rianec","image":"https:\/\/pbs.twimg.com\/profile_images\/1335945743\/Foto_Twitter_normal.jpg","description":"El asunto no es romper estructuras, si no saber que hacer con los pedazos. \nAlergologa con pediatr\u00eda en la mochila. Madre \ud83d\udc76\ud83c\udffc en aDOSlecencia.","id_on_source":"NocciolaHR","tweeter_id":"76725872","geo":{"lt":28.09973,"ln":-15.41343,"country":"ES"},"followers":139},"tweet_id":"866934811373469697"},{"url":"http:\/\/twitter.com\/animesh1977\/statuses\/866938811745521664","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T08:48:14+00:00","author":{"name":"Ani","url":"https:\/\/sites.google.com\/site\/sharmaanimesh\/","image":"https:\/\/pbs.twimg.com\/profile_images\/734400513341526017\/jJnZP2H0_normal.jpg","id_on_source":"animesh1977","tweeter_id":"15936294","geo":{"lt":60.39299,"ln":5.32415,"country":"NO"},"followers":1652},"tweet_id":"866938811745521664"},{"url":"http:\/\/twitter.com\/franj_garcia\/statuses\/866941711926349824","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-23T08:59:45+00:00","author":{"name":"Francisco Garc\u00eda \uf8ff","url":"http:\/\/www.doctorgarciasanchez.com","image":"https:\/\/pbs.twimg.com\/profile_images\/885263165646405632\/EyykzrH1_normal.jpg","description":"M\u00e9dico Especialista en Medicina Interna","id_on_source":"franj_garcia","tweeter_id":"86499606","geo":{"lt":40.42526,"ln":-3.69063,"country":"ES"},"followers":180},"tweet_id":"866941711926349824"},{"url":"http:\/\/twitter.com\/pedrojmarcos\/statuses\/866944073281789952","license":"gnip","rt":["pontepedrat"],"citation_ids":[20391756],"posted_on":"2017-05-23T09:09:08+00:00","author":{"name":"Pedro J Marcos","image":"https:\/\/pbs.twimg.com\/profile_images\/781733400294096896\/puO5EHQg_normal.jpg","description":"Neum\u00f3logo buscando respuestas... Hospital Universitario de A Coru\u00f1a. Presidente de la @sogapar","id_on_source":"pedrojmarcos","tweeter_id":"182796487","geo":{"lt":43.37135,"ln":-8.396,"country":"ES"},"followers":551},"tweet_id":"866944073281789952"},{"url":"http:\/\/twitter.com\/_medjournal\/statuses\/866966455165779968","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T10:38:05+00:00","author":{"name":"Internet Medical","url":"http:\/\/medjournal.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1096739216\/101203760_normal.jpg","description":"The Internet Medical Journal","id_on_source":"_medjournal","tweeter_id":"164579558","geo":{"lt":36.17497,"ln":-115.13722,"country":"US"},"followers":4538},"tweet_id":"866966455165779968"},{"url":"http:\/\/twitter.com\/asthma_papers\/statuses\/866988612289568773","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T12:06:07+00:00","author":{"name":"Asthma Papers","url":"https:\/\/github.com\/roblanf\/phypapers","image":"https:\/\/pbs.twimg.com\/profile_images\/439482171208646656\/OWe4b0kE_normal.jpeg","description":"RSS feed for #asthma papers in #Pubmed. Create a feed of your own using instructions here:","id_on_source":"asthma_papers","tweeter_id":"2366030767","geo":{"lt":null,"ln":null},"followers":565},"tweet_id":"866988612289568773"},{"url":"http:\/\/twitter.com\/AstraZenecaUS\/statuses\/866991349576466432","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T12:17:00+00:00","author":{"name":"AstraZenecaUS","url":"https:\/\/www.astrazeneca-us.com\/media\/astrazeneca-us-blog.html","image":"https:\/\/pbs.twimg.com\/profile_images\/1488204784\/AZ_SYMBOL_RGB_normal.jpg","description":"The official Twitter feed for AstraZeneca US. For more info visit http:\/\/www.astrazeneca-us.com.","id_on_source":"AstraZenecaUS","tweeter_id":"18723114","geo":{"lt":39.74595,"ln":-75.54659,"country":"US"},"followers":54176},"tweet_id":"866991349576466432"},{"url":"http:\/\/twitter.com\/Innoplexus\/statuses\/867001871210225665","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T12:58:48+00:00","author":{"name":"Innoplexus","url":"https:\/\/iplexus.ai","image":"https:\/\/pbs.twimg.com\/profile_images\/666885917408292868\/czjcP--0_normal.jpg","description":"We are The Intelligence Machine for Life sciences research. Our solutions use Artificial Intelligence and Machine Learning to help expedite drug development.","id_on_source":"Innoplexus","tweeter_id":"372842840","geo":{"lt":null,"ln":null},"followers":887},"tweet_id":"867001871210225665"},{"url":"http:\/\/twitter.com\/KhouryMD\/statuses\/867014083303927808","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T13:47:20+00:00","author":{"name":"Paneez Khoury MD","image":"https:\/\/pbs.twimg.com\/profile_images\/862809016828739585\/PfVqlAAI_normal.jpg","description":"Physician (IM, AI) tweeting #foodallergy, #eosinophils, #healthtech. All tweets my own, not employers. RT not endorsements.","id_on_source":"KhouryMD","tweeter_id":"335052515","geo":{"lt":38.91706,"ln":-77.00025,"country":"US"},"followers":105},"tweet_id":"867014083303927808"},{"url":"http:\/\/twitter.com\/markcl208041\/statuses\/867022241933926400","license":"gnip","rt":["AstraZenecaUS"],"citation_ids":[20391756],"posted_on":"2017-05-23T14:19:45+00:00","author":{"name":"markcl208041","image":"https:\/\/pbs.twimg.com\/profile_images\/872425106907082752\/78qP4CKU_normal.jpg","description":"Scientist, Oncology, Immuno-oncology, precision medicine.Oncogene.","id_on_source":"markcl208041","tweeter_id":"794534353875259392","geo":{"lt":null,"ln":null},"followers":121},"tweet_id":"867022241933926400"},{"url":"http:\/\/twitter.com\/BruderStapleton\/statuses\/867015835558137856","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T13:54:18+00:00","author":{"name":"F Bruder Stapleton","image":"https:\/\/pbs.twimg.com\/profile_images\/584611212056403968\/oIZh9NhS_normal.jpg","description":"Chairman of Pediatrics, University of Washington and Seattle Children's, Editor-in-Chief NEJM J Watch Peds and Adol Med All comments reflect personal views.","id_on_source":"BruderStapleton","tweeter_id":"3109045874","geo":{"lt":null,"ln":null},"followers":744},"tweet_id":"867015835558137856"},{"url":"http:\/\/twitter.com\/manasigh\/statuses\/867035949372407808","license":"gnip","rt":["PharmacyJoe"],"citation_ids":[20391756],"posted_on":"2017-05-23T15:14:13+00:00","author":{"name":"Mana","image":"https:\/\/pbs.twimg.com\/profile_images\/643451195768508417\/pYMSRWMl_normal.jpg","id_on_source":"manasigh","tweeter_id":"473483410","geo":{"lt":null,"ln":null},"followers":209},"tweet_id":"867035949372407808"},{"url":"http:\/\/twitter.com\/Prescriberight\/statuses\/867050373642674177","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-23T16:11:32+00:00","author":{"name":"Scot Walker","url":"http:\/\/www.prescriberight.com\/pharmaceutical-pipeline-tracker.html","image":"https:\/\/pbs.twimg.com\/profile_images\/857613402469933057\/rpM84HvK_normal.jpg","description":"Pharmaceutical pipeline expert.  Track drugs in development at http:\/\/PrescribeRight.com","id_on_source":"Prescriberight","tweeter_id":"3364985680","geo":{"lt":null,"ln":null},"followers":54},"tweet_id":"867050373642674177"},{"url":"http:\/\/twitter.com\/DesanctisJuan\/statuses\/867072498231279617","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-05-23T17:39:27+00:00","author":{"name":"Juan B. De Sanctis","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000711357584\/5281967f704a91da496468cab3872fc2_normal.jpeg","description":"Profesor Titular y Director. Instituto de Inmunolog\u00eda. UCV","id_on_source":"DesanctisJuan","tweeter_id":"2176625564","geo":{"lt":8,"ln":-66,"country":"VE"},"followers":199},"tweet_id":"867072498231279617"},{"url":"http:\/\/twitter.com\/karadag68\/statuses\/867232107847876608","license":"gnip","rt":["AstraZenecaUS"],"citation_ids":[20391756],"posted_on":"2017-05-24T04:13:41+00:00","author":{"name":"B\u00fclent Karadag","image":"https:\/\/pbs.twimg.com\/profile_images\/504021404702871552\/IDruOMiT_normal.jpeg","description":"Marmara Universitesi, Profes\u00f6r, Paediatric pulmonologist. Hayatta herkesten \u00f6\u011frenecek bir\u015feyim var, her an\u0131n de\u011ferlendirilmesi ve zevk al\u0131nmas\u0131=Mutluluk.","id_on_source":"karadag68","tweeter_id":"103232470","geo":{"lt":41.03508,"ln":28.98331,"country":"TR"},"followers":4219},"tweet_id":"867232107847876608"},{"url":"http:\/\/twitter.com\/tomheston\/statuses\/867226536201641984","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-24T03:51:33+00:00","author":{"name":"Tom Heston","url":"http:\/\/tomheston.com","image":"https:\/\/pbs.twimg.com\/profile_images\/452650157050302464\/-kGG7sgd_normal.png","description":"I help people make wise health decisions. Theese are my medical newsfeed tweets. Follow @tomhestonmd for my personal tweets.","id_on_source":"tomheston","tweeter_id":"21013461","geo":{"lt":44.25,"ln":17.83333,"country":"BA"},"followers":83106},"tweet_id":"867226536201641984"},{"url":"http:\/\/twitter.com\/itziarlarrodele\/statuses\/867403068752752642","license":"gnip","rt":["FarmaciaOesteAP"],"citation_ids":[20391756],"posted_on":"2017-05-24T15:33:01+00:00","author":{"name":"itziar larrode leci\u00f1","image":"https:\/\/pbs.twimg.com\/profile_images\/3680872130\/a47acbcb306c25255bef3873c7bc03b6_normal.jpeg","description":"Farmaceutica Especialista en Farmacia Hospitalaria. Si lo puedes so\u00f1ar lo puedes lograr","id_on_source":"itziarlarrodele","tweeter_id":"619880269","geo":{"lt":null,"ln":null},"followers":376},"tweet_id":"867403068752752642"},{"url":"http:\/\/twitter.com\/youareinformed\/statuses\/867275383388819456","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-24T07:05:39+00:00","author":{"name":"Tom","url":"http:\/\/keepingyouinformed.ws","image":"https:\/\/pbs.twimg.com\/profile_images\/453614701675442177\/qvsUc2sn_normal.png","description":"Keeping you informed is our top priority.","id_on_source":"youareinformed","tweeter_id":"341140588","geo":{"lt":null,"ln":null},"followers":4468},"tweet_id":"867275383388819456"},{"url":"http:\/\/twitter.com\/AURELIN15\/statuses\/867476962129965056","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-24T20:26:39+00:00","author":{"name":"NESTOR DE LA CRUZ","image":"https:\/\/pbs.twimg.com\/profile_images\/773286212614381568\/C_MbsCFC_normal.jpg","description":"Medico Especialista Medicina Interna, Sub Especialista  Medicina Nuclear.","id_on_source":"AURELIN15","tweeter_id":"147179937","geo":{"lt":4.25,"ln":-74.18333,"country":"CO"},"followers":295},"tweet_id":"867476962129965056"},{"url":"http:\/\/twitter.com\/FarmaciaOesteAP\/statuses\/867283323160330240","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-24T07:37:12+00:00","author":{"name":"Farmacia AP DAOeste","image":"https:\/\/pbs.twimg.com\/profile_images\/815853302097309696\/Hunxmo0j_normal.jpg","description":"Farmac\u00e9utic@s de atenci\u00f3n primaria de la Direcci\u00f3n Asistencial Oeste del Servicio Madrile\u00f1o de Salud. Informaci\u00f3n exclusivamente para profesionales sanitarios.","id_on_source":"FarmaciaOesteAP","tweeter_id":"256435789","geo":{"lt":40.34582,"ln":-3.82487,"country":"ES"},"followers":2617},"tweet_id":"867283323160330240"},{"url":"http:\/\/twitter.com\/docalergias\/statuses\/867353826411544576","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-24T12:17:21+00:00","author":{"name":"Dr Alexei Gonzalez","image":"https:\/\/pbs.twimg.com\/profile_images\/754761432239976448\/2rL-ye1k_normal.jpg","description":"Allergist\/Immunologist, Associate Professor at @MayoClinic. Tweets are mine and not medical advice.","id_on_source":"docalergias","tweeter_id":"744219295585017856","geo":{"lt":30.29469,"ln":-81.39314,"country":"US"},"followers":187},"tweet_id":"867353826411544576"},{"url":"http:\/\/twitter.com\/JMDallergy\/statuses\/867363436484841473","license":"gnip","rt":["docalergias"],"citation_ids":[20391756],"posted_on":"2017-05-24T12:55:32+00:00","author":{"name":"Joshua M Dorn, MD","image":"https:\/\/pbs.twimg.com\/profile_images\/857587855870246912\/rTpEcczc_normal.jpg","description":"#Allergy\/Immunology Fellow @mayoclinic | with \ud83e\udd5c allergy | #Foodallergy dad | Interested in all things A\/I and patient-care! Tweets\/views my own|not med advice","id_on_source":"JMDallergy","tweeter_id":"1319283121","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":452},"tweet_id":"867363436484841473"},{"url":"http:\/\/twitter.com\/RevistaSOCAMPAR\/statuses\/867630706406678528","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-25T06:37:34+00:00","author":{"name":"Revista SOCAMPAR","url":"http:\/\/www.revista-socampar.com","image":"https:\/\/pbs.twimg.com\/profile_images\/803714192217899010\/MC0vSJ1Y_normal.jpg","description":"Revista cient\u00edfica de Patolog\u00eda Respiratoria de la SOCAMPAR (Sociedad Castellano Manchega de Patolog\u00eda Respiratoria)\nISSN: 2529 -9859","id_on_source":"RevistaSOCAMPAR","tweeter_id":"803711814492188672","geo":{"lt":null,"ln":null},"followers":557},"tweet_id":"867630706406678528"},{"url":"http:\/\/twitter.com\/Aller_MD\/statuses\/867923353239244800","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-26T02:00:27+00:00","author":{"name":"Juan C Ivancevich MD","image":"https:\/\/pbs.twimg.com\/profile_images\/906525202787520514\/NdEfNrQI_normal.jpg","description":"Allergist - Twittering on #allergy, #asthma & #immunology. Associate Professor of Immunology, del Salvador University, WAO website Chief Editor","id_on_source":"Aller_MD","tweeter_id":"23184067","geo":{"lt":-34.61315,"ln":-58.37723,"country":"AR"},"followers":5432},"tweet_id":"867923353239244800"},{"url":"http:\/\/twitter.com\/afsb2013\/statuses\/867939950473379846","license":"gnip","rt":["sergiobarbaecua"],"citation_ids":[20391756],"posted_on":"2017-05-26T03:06:24+00:00","author":{"name":"Antonio","url":"http:\/\/www.py.med.br","image":"https:\/\/pbs.twimg.com\/profile_images\/1125094201\/Avatar_AFSB_3_normal.JPG","description":"Pathology professor. Doctor. Interest in development in the images digital processing area using Python.","id_on_source":"afsb2013","tweeter_id":"66429081","geo":{"lt":-9.66583,"ln":-35.73528,"country":"BR"},"followers":586},"tweet_id":"867939950473379846"},{"url":"http:\/\/twitter.com\/SocLatAlergia\/statuses\/867971373859086337","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-26T05:11:16+00:00","author":{"name":"SLaai","url":"http:\/\/www.slaai.org","image":"https:\/\/pbs.twimg.com\/profile_images\/469173940116393986\/4DtHZNic_normal.png","description":"Sociedad Latinoamericana de Alergia, Asma e Inmunolog\u00eda","id_on_source":"SocLatAlergia","tweeter_id":"367878837","geo":{"lt":null,"ln":null},"followers":1252},"tweet_id":"867971373859086337"},{"url":"http:\/\/twitter.com\/Interasma\/statuses\/867971541492842501","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-26T05:11:56+00:00","author":{"name":"Interasma","url":"http:\/\/www.interasma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/481070665450016770\/o6EbOA8x_normal.jpeg","description":"Interasma is an international health organization focused on all aspects of asthma which bridges the gap between academia and the world of clinical practice.","id_on_source":"Interasma","tweeter_id":"147594153","geo":{"lt":null,"ln":null},"followers":1580},"tweet_id":"867971541492842501"},{"url":"http:\/\/twitter.com\/FUNDACIONLIBRA\/statuses\/867971689241468929","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-26T05:12:31+00:00","author":{"name":"Fundaci\u00f3n Libra","url":"http:\/\/www.fundacionlibra.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1130674087\/logo_normal.jpg","description":"Fundaci\u00f3n LIBRA (Fundaci\u00f3n Lucha Integral contra la Broncopat\u00eda, la Rinitis y el Asma)","id_on_source":"FUNDACIONLIBRA","tweeter_id":"194818089","geo":{"lt":null,"ln":null},"followers":359},"tweet_id":"867971689241468929"},{"url":"http:\/\/twitter.com\/ARIAGuideline\/statuses\/867971922507710465","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-26T05:13:27+00:00","author":{"name":"ARIAguideline","url":"http:\/\/www.euforea.eu\/aria.html","image":"https:\/\/pbs.twimg.com\/profile_images\/879696169118683136\/oxS9M72d_normal.jpg","description":"The ARIA (Allergic Rhinitis and its Impact on Asthma) initiative aims to educate and implement evidence-based management of allergic rhinitis and asthma","id_on_source":"ARIAGuideline","tweeter_id":"367561906","geo":{"lt":null,"ln":null},"followers":1351},"tweet_id":"867971922507710465"},{"url":"http:\/\/twitter.com\/LeoUzych\/statuses\/867910933984628736","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-26T01:11:06+00:00","author":{"name":"leo uzych","image":"https:\/\/pbs.twimg.com\/profile_images\/1316390664\/004_1__normal.JPG","description":"Bachelor of Arts degree, magna cum laude, University of Pennsylvania; Master of Public Health degree, Columbia University","id_on_source":"LeoUzych","tweeter_id":"275654150","geo":{"lt":40.27245,"ln":-76.90567,"country":"US"},"followers":202},"tweet_id":"867910933984628736"},{"url":"http:\/\/twitter.com\/AURELIN15\/statuses\/868064212551073792","license":"gnip","rt":["Aller_MD"],"citation_ids":[20391756],"posted_on":"2017-05-26T11:20:10+00:00","author":{"name":"NESTOR DE LA CRUZ","image":"https:\/\/pbs.twimg.com\/profile_images\/773286212614381568\/C_MbsCFC_normal.jpg","description":"Medico Especialista Medicina Interna, Sub Especialista  Medicina Nuclear.","id_on_source":"AURELIN15","tweeter_id":"147179937","geo":{"lt":4.25,"ln":-74.18333,"country":"CO"},"followers":295},"tweet_id":"868064212551073792"},{"url":"http:\/\/twitter.com\/NottinghamRRU\/statuses\/868092074373120000","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-26T13:10:53+00:00","author":{"name":"NottinghamRRU","url":"http:\/\/www.nrru.org","image":"https:\/\/pbs.twimg.com\/profile_images\/720581255960596480\/s0lfReH7_normal.jpg","description":"Nottingham Respiratory Research Unit (NRRU) is dedicated to advancing knowledge and treatments for people with respiratory diseases like Asthma, COPD, ILD & CF","id_on_source":"NottinghamRRU","tweeter_id":"476666568","geo":{"lt":null,"ln":null},"followers":559},"tweet_id":"868092074373120000"},{"url":"http:\/\/twitter.com\/sergiobarbaecua\/statuses\/868122522507673600","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-26T15:11:52+00:00","author":{"name":"Sergio Barba","url":"http:\/\/www.aaaalergia.com","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","id_on_source":"sergiobarbaecua","tweeter_id":"188846475","geo":{"lt":-0.22985,"ln":-78.52495,"country":"EC"},"followers":61},"tweet_id":"868122522507673600"},{"url":"http:\/\/twitter.com\/drarequena\/statuses\/868421068750508032","license":"gnip","rt":["DoctorBarcelo"],"citation_ids":[20391756],"posted_on":"2017-05-27T10:58:11+00:00","author":{"name":"GloriaRequena","url":"http:\/\/www.facebook.com\/#!\/pages\/Consulta-Alergia-Dra-Requena\/173336776050017","image":"https:\/\/pbs.twimg.com\/profile_images\/2218872926\/17032012436_normal.jpg","description":"Alerg\u00f3loga, Farmac\u00f3loga Cl\u00ednica","id_on_source":"drarequena","tweeter_id":"580314999","geo":{"lt":36.77262,"ln":-4.10045,"country":"ES"},"followers":843},"tweet_id":"868421068750508032"},{"url":"http:\/\/twitter.com\/DoctorBarcelo\/statuses\/868411247439613952","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-27T10:19:10+00:00","author":{"name":"Doctor Barcel\u00f3","url":"http:\/\/www.doctorbarcelo.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2186773285\/Logo_DrBarcel__normal.jpg","description":"Alerg\u00f3logo Dr.Barcel\u00f3\r\nEstudio y tratamiento de alergias para ni\u00f1os y adultos en M\u00e1laga","id_on_source":"DoctorBarcelo","tweeter_id":"569820932","geo":{"lt":36.77262,"ln":-4.10045,"country":"ES"},"followers":260},"tweet_id":"868411247439613952"},{"url":"http:\/\/twitter.com\/Bmestar\/statuses\/869322641953476608","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-29T22:40:43+00:00","author":{"name":"Beth Staropoli","image":"https:\/\/pbs.twimg.com\/profile_images\/455889959619031040\/GBpOVI4P_normal.jpeg","description":"General Manager, Schweiger Dermatology Group, Political, Economic, Medical & Social Commentary.","id_on_source":"Bmestar","tweeter_id":"174463647","geo":{"lt":43.00035,"ln":-75.4999,"country":"US"},"followers":115},"tweet_id":"869322641953476608"},{"url":"http:\/\/twitter.com\/Martapc75\/statuses\/869433188589998081","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-30T06:00:00+00:00","author":{"name":"Marta Palop Cervera","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","id_on_source":"Martapc75","tweeter_id":"270360810","geo":{"lt":null,"ln":null},"followers":0},"tweet_id":"869433188589998081"},{"url":"http:\/\/twitter.com\/Marta_Palop\/statuses\/869434747675652096","license":"gnip","citation_ids":[20391756],"posted_on":"2017-05-30T06:06:11+00:00","author":{"name":"Marta Palop","image":"https:\/\/pbs.twimg.com\/profile_images\/886304328646094852\/q7UrP_uM_normal.jpg","description":"M\u00e9dico, neum\u00f3loga, inquieta, aprendiendo cada d\u00eda. Los 40 son los nuevos 30, keep calm!","id_on_source":"Marta_Palop","tweeter_id":"355065025","geo":{"lt":null,"ln":null},"followers":344},"tweet_id":"869434747675652096"},{"url":"http:\/\/twitter.com\/air_garcia\/statuses\/870537444332105728","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-02T07:07:55+00:00","author":{"name":"Ana Rigueira","url":"http:\/\/epanoramix.wordpress.com","image":"https:\/\/pbs.twimg.com\/profile_images\/900441605248884738\/jXj0aoCw_normal.jpg","description":"Obrera especializada del sistema sanitario p\u00fablico, sector farmacia. Particularmente preocupada por el trato digno y profesional de los mayores con demencia.","id_on_source":"air_garcia","tweeter_id":"2858472663","geo":{"lt":40,"ln":-4,"country":"ES"},"followers":377},"tweet_id":"870537444332105728"},{"url":"http:\/\/twitter.com\/PLMcCarthyMD\/statuses\/870581325618700289","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-02T10:02:17+00:00","author":{"name":"Philip McCarthy","image":"https:\/\/pbs.twimg.com\/profile_images\/466351626219823104\/K2IQ5P6I_normal.jpeg","description":"Interested in hematopoietic cell transplantation and hematologic disorders with emphasis on multiple myeloma, AML, ALL, MDS, NHL, HL, CLL, CML","id_on_source":"PLMcCarthyMD","tweeter_id":"454898193","geo":{"lt":42.88645,"ln":-78.87837,"country":"US"},"followers":1954},"tweet_id":"870581325618700289"},{"url":"http:\/\/twitter.com\/ATS_BSHSR\/statuses\/870744362484985856","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-02T20:50:08+00:00","author":{"name":"ATS BSHSR","image":"https:\/\/pbs.twimg.com\/profile_images\/814593908290318336\/aSgFcoLE_normal.jpg","description":"American Thoracic Society Behavioral Science Health Services Research Assembly. Tweeting most recent research. Mission: http:\/\/buff.ly\/1IhnJCS","id_on_source":"ATS_BSHSR","tweeter_id":"3236232894","geo":{"lt":null,"ln":null},"followers":411},"tweet_id":"870744362484985856"},{"url":"http:\/\/twitter.com\/jvalverde64\/statuses\/872092879937830912","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-06T14:08:39+00:00","author":{"name":"Jos\u00e9 Valverde-Molina","url":"https:\/\/www.researchgate.net\/profile\/Jose_Valverde-Molina2","image":"https:\/\/pbs.twimg.com\/profile_images\/688447568813146122\/irDhuNWn_normal.jpg","description":"Pediatra Neum\u00f3logo. Jefe de Secci\u00f3n de Pediatr\u00eda. Hospital Universitario los Arcos del Mar Menor.\nPresidente de la SPSE","id_on_source":"jvalverde64","tweeter_id":"1055305087","geo":{"lt":38,"ln":-1.5,"country":"ES"},"followers":704},"tweet_id":"872092879937830912"},{"url":"http:\/\/twitter.com\/LuisZuritaG\/statuses\/872115436292276224","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-06T15:38:17+00:00","author":{"name":"Luis Zurita G.","url":"http:\/\/www.artritisylupus.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1916335212\/image_normal.jpg","description":"Internista-Reumatologo, interes especial en Lupus,Artritis, musica clasica y vino tinto, hincha de Emelec y Real Madrid","id_on_source":"LuisZuritaG","tweeter_id":"417387026","geo":{"lt":-2.20584,"ln":-79.90795,"country":"EC"},"followers":158},"tweet_id":"872115436292276224"},{"url":"http:\/\/twitter.com\/LuisZuritaG\/statuses\/872123046919884800","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-06T16:08:32+00:00","author":{"name":"Luis Zurita G.","url":"http:\/\/www.artritisylupus.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1916335212\/image_normal.jpg","description":"Internista-Reumatologo, interes especial en Lupus,Artritis, musica clasica y vino tinto, hincha de Emelec y Real Madrid","id_on_source":"LuisZuritaG","tweeter_id":"417387026","geo":{"lt":-2.20584,"ln":-79.90795,"country":"EC"},"followers":158},"tweet_id":"872123046919884800"},{"url":"http:\/\/twitter.com\/iBiznezz\/statuses\/872238693033136128","license":"gnip","rt":["LuisZuritaG"],"citation_ids":[20391756],"posted_on":"2017-06-06T23:48:04+00:00","author":{"name":"Don of all DONS\u2122","image":"https:\/\/pbs.twimg.com\/profile_images\/876972583274631168\/WWlsPaO-_normal.jpg","description":"MD.\nEn la meditaci\u00f3n lo encuentro todo.\nEst.1994 \nInstagram: iBiznezz","id_on_source":"iBiznezz","tweeter_id":"193417027","geo":{"lt":4.25,"ln":-74.18333,"country":"CO"},"followers":508},"tweet_id":"872238693033136128"},{"url":"http:\/\/twitter.com\/juanjbosch\/statuses\/872249803643682816","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-07T00:32:13+00:00","author":{"name":"Juan jose bosch","image":"https:\/\/pbs.twimg.com\/profile_images\/863831901425061888\/vs9h6UI9_normal.jpg","description":"Medico, pediatra. Neumonologo infantil. Hospital Universitario Austral. Hospital de Ni\u00f1os Ricardo Gutierrez.","id_on_source":"juanjbosch","tweeter_id":"752582724","geo":{"lt":null,"ln":null},"followers":44},"tweet_id":"872249803643682816"},{"url":"http:\/\/twitter.com\/dilshad_moosa\/statuses\/876029520612077569","license":"gnip","rt":["SammyG_MD"],"citation_ids":[20391756],"posted_on":"2017-06-17T10:51:28+00:00","author":{"name":"Dilshad Moosa","image":"https:\/\/pbs.twimg.com\/profile_images\/490095318684688384\/-vbMLr5Y_normal.jpeg","description":"Respiratory Therapist, Knowledge Translation Practitioner, Lung Health Aficionado, Travelling and Hiking is my thing, Mom of Zey and Mikhail","id_on_source":"dilshad_moosa","tweeter_id":"136256861","geo":{"lt":null,"ln":null},"followers":80},"tweet_id":"876029520612077569"},{"url":"http:\/\/twitter.com\/dilshad_moosa\/statuses\/876029603147632641","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-17T10:51:47+00:00","author":{"name":"Dilshad Moosa","image":"https:\/\/pbs.twimg.com\/profile_images\/490095318684688384\/-vbMLr5Y_normal.jpeg","description":"Respiratory Therapist, Knowledge Translation Practitioner, Lung Health Aficionado, Travelling and Hiking is my thing, Mom of Zey and Mikhail","id_on_source":"dilshad_moosa","tweeter_id":"136256861","geo":{"lt":null,"ln":null},"followers":80},"tweet_id":"876029603147632641"},{"url":"http:\/\/twitter.com\/NEJM\/statuses\/877642318219706368","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-21T21:40:09+00:00","author":{"name":"NEJM","url":"http:\/\/NEJM.org","image":"https:\/\/pbs.twimg.com\/profile_images\/893483773362393088\/US3DliFV_normal.jpg","description":"The New England Journal of Medicine (http:\/\/NEJM.org) is the world\u2019s leading medical journal and website.","id_on_source":"NEJM","tweeter_id":"25950355","geo":{"lt":42.35843,"ln":-71.05977,"country":"US"},"followers":447795},"tweet_id":"877642318219706368"},{"url":"http:\/\/twitter.com\/monitor_PH\/statuses\/877642734504468482","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-21T21:41:48+00:00","author":{"name":"Pub Health Monitor","image":"https:\/\/pbs.twimg.com\/profile_images\/870025490576195584\/-j8sNx6W_normal.jpg","description":"Surveying the field of Public Health. Maintained by @thisisdaryn.\n\nCuration of sources is a work in progress. Send feedback to darynr at gmail.","id_on_source":"monitor_PH","tweeter_id":"869967070984851457","geo":{"lt":null,"ln":null},"followers":182},"tweet_id":"877642734504468482"},{"url":"http:\/\/twitter.com\/dccc_phd\/statuses\/877643500409442305","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-21T21:44:50+00:00","author":{"id_on_source":"dccc_phd","tweeter_id":"2365729350","geo":{"lt":42.35843,"ln":-71.05977,"country":"US"}},"tweet_id":"877643500409442305"},{"url":"http:\/\/twitter.com\/THebertMcGill\/statuses\/877644378012909569","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-21T21:48:20+00:00","author":{"name":"Terry H\u00e9bert","image":"https:\/\/pbs.twimg.com\/profile_images\/3692558110\/d2221dcaa41123dc08b3717e79d90d48_normal.jpeg","description":"Scientist;Interested in drug discovery and cellular signalling- opinions my own","id_on_source":"THebertMcGill","tweeter_id":"1447788685","geo":{"lt":null,"ln":null},"followers":779},"tweet_id":"877644378012909569"},{"url":"http:\/\/twitter.com\/SOLTMANY\/statuses\/877644473601105922","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-21T21:48:43+00:00","author":{"name":"Dorota","image":"https:\/\/pbs.twimg.com\/profile_images\/823536777763966976\/RDQkP00W_normal.jpg","id_on_source":"SOLTMANY","tweeter_id":"32769379","geo":{"lt":null,"ln":null},"followers":505},"tweet_id":"877644473601105922"},{"url":"http:\/\/twitter.com\/wheezemd\/statuses\/877649396262879232","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-21T22:08:16+00:00","author":{"name":"Michael Blaiss, MD","image":"https:\/\/pbs.twimg.com\/profile_images\/756202019170443265\/0V42zMQP_normal.jpg","description":"Allergist, Executive Medical Director of the American College of Allergy, Asthma, and Immunology","id_on_source":"wheezemd","tweeter_id":"13557562","geo":{"lt":null,"ln":null},"followers":3496},"tweet_id":"877649396262879232"},{"url":"http:\/\/twitter.com\/JMDallergy\/statuses\/877667647583916032","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-21T23:20:48+00:00","author":{"name":"Joshua M Dorn, MD","image":"https:\/\/pbs.twimg.com\/profile_images\/857587855870246912\/rTpEcczc_normal.jpg","description":"#Allergy\/Immunology Fellow @mayoclinic | with \ud83e\udd5c allergy | #Foodallergy dad | Interested in all things A\/I and patient-care! Tweets\/views my own|not med advice","id_on_source":"JMDallergy","tweeter_id":"1319283121","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":452},"tweet_id":"877667647583916032"},{"url":"http:\/\/twitter.com\/lee_jasonk\/statuses\/877667904652800000","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-21T23:21:49+00:00","author":{"name":"Jason K Lee","url":"http:\/\/www.jasonleemd.com","image":"https:\/\/pbs.twimg.com\/profile_images\/456886375137034241\/yDFoRIIi_normal.png","description":"Jason K Lee, MD, FRCPC Internal Medicine, Clinical Immunology & Allergy, FAAAAI. Dedicated to patient empowerment! All tweets not related to duties at any org.","id_on_source":"lee_jasonk","tweeter_id":"1417107000","geo":{"lt":43.70011,"ln":-79.4163,"country":"CA"},"followers":600},"tweet_id":"877667904652800000"},{"url":"http:\/\/twitter.com\/CardioLearn\/statuses\/877681501734940673","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T00:15:51+00:00","author":{"name":"CardioLearn","image":"https:\/\/pbs.twimg.com\/profile_images\/877679376086839297\/zPwpXzeD_normal.jpg","description":"Foro de Cardiolog\u00eda. Gu\u00edas Internacionales. Investigaci\u00f3n.  Casos Cl\u00ednicos.","id_on_source":"CardioLearn","tweeter_id":"481547061","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":192},"tweet_id":"877681501734940673"},{"url":"http:\/\/twitter.com\/ClinicalBriefs\/statuses\/877685155674107904","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T00:30:22+00:00","author":{"name":"Holden Caulfield PhD","url":"http:\/\/Clinical-Briefs.com","image":"https:\/\/pbs.twimg.com\/profile_images\/779016881428688897\/TFyQGGxg_normal.jpg","description":"Indep writer @ClinicalBriefs: Medical insights, simplified\u2122. Follow for news on medical research and policy. Opinions are my own.","id_on_source":"ClinicalBriefs","tweeter_id":"3810014352","geo":{"lt":null,"ln":null},"followers":348},"tweet_id":"877685155674107904"},{"url":"http:\/\/twitter.com\/martinrafco\/statuses\/877688061638922240","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T00:41:55+00:00","author":{"name":"Martin Correa","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000723541756\/cfc2d95ee97474491e46578948293c38_normal.jpeg","id_on_source":"martinrafco","tweeter_id":"2176175740","geo":{"lt":null,"ln":null},"followers":56},"tweet_id":"877688061638922240"},{"url":"http:\/\/twitter.com\/kdahal57\/statuses\/877697205477527552","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T01:18:15+00:00","author":{"name":"kumud dahal","image":"https:\/\/pbs.twimg.com\/profile_images\/2949821637\/24dcca3db72b2a583a2596053ac8f170_normal.jpeg","description":"Interests: Infection in compromised hosts HIV\/ Hep C Tropical Infections Infectious Disease epidemiology","id_on_source":"kdahal57","tweeter_id":"552644651","geo":{"lt":40.00032,"ln":-89.25037,"country":"US"},"followers":183},"tweet_id":"877697205477527552"},{"url":"http:\/\/twitter.com\/KeprosSparrow\/statuses\/877704916982259712","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-22T01:48:53+00:00","author":{"name":"John Paul Kepros","image":"https:\/\/pbs.twimg.com\/profile_images\/681507791312449536\/ywM0fy-5_normal.jpg","id_on_source":"KeprosSparrow","tweeter_id":"4633799847","geo":{"lt":null,"ln":null},"followers":80},"tweet_id":"877704916982259712"},{"url":"http:\/\/twitter.com\/YNHallak\/statuses\/877720225780613120","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T02:49:43+00:00","author":{"name":"Dr. Yaacoub Hallak","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000778225794\/7db6f1f4181fedf82f9ff186b94f50e0_normal.jpeg","description":"Birds Can Fly & So Can I... RTs; not endorsements! See Brief Profile: http:\/\/www.emerson.edu\/academics\/departments\/journalism\/faculty?faculty_id=2769&filter=P","id_on_source":"YNHallak","tweeter_id":"49794620","geo":{"lt":42.35843,"ln":-71.05977,"country":"US"},"followers":44509},"tweet_id":"877720225780613120"},{"url":"http:\/\/twitter.com\/jaygeorge60\/statuses\/877724176546750464","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T03:05:25+00:00","author":{"name":"Jay George","image":"https:\/\/pbs.twimg.com\/profile_images\/861414269711200256\/U0C4MNzY_normal.jpg","id_on_source":"jaygeorge60","tweeter_id":"1540643960","geo":{"lt":28.75054,"ln":-82.5001,"country":"US"},"followers":395},"tweet_id":"877724176546750464"},{"url":"http:\/\/twitter.com\/banavarrete\/statuses\/877752300638523392","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T04:57:10+00:00","author":{"name":"Bernardino Alcazar","image":"https:\/\/pbs.twimg.com\/profile_images\/745325783267348480\/8Df2MwvM_normal.jpg","description":"Casado con la mujer de mi vida. Neum\u00f3logo vocacional. Padre de familia muy numerosa","id_on_source":"banavarrete","tweeter_id":"356711852","geo":{"lt":12.11667,"ln":-61.66667,"country":"GD"},"followers":882},"tweet_id":"877752300638523392"},{"url":"http:\/\/twitter.com\/pulmonology101\/statuses\/877765895300554757","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T05:51:12+00:00","author":{"name":"Carlos Celis","image":"https:\/\/pbs.twimg.com\/profile_images\/883284771522138113\/7du6nIXL_normal.jpg","description":"Pulmonologist, Hospital Universitario San Ignacio. Professor, Faculty of Medicine @UniJaveriana. cacelis.neumo@gmail.com","id_on_source":"pulmonology101","tweeter_id":"771841009","geo":{"lt":4.25,"ln":-74.18333,"country":"CO"},"followers":2358},"tweet_id":"877765895300554757"},{"url":"http:\/\/twitter.com\/SenectusSAS\/statuses\/877785066084200448","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T07:07:22+00:00","author":{"name":"Senectus","url":"http:\/\/www.senectus.it","image":"https:\/\/pbs.twimg.com\/profile_images\/488196838059945984\/3rx5j1-G_normal.jpeg","description":"Servizi, formazione e prodotti per un invecchiamento di successo (Bologna)","id_on_source":"SenectusSAS","tweeter_id":"2492384533","geo":{"lt":44.49381,"ln":11.33875,"country":"IT"},"followers":381},"tweet_id":"877785066084200448"},{"url":"http:\/\/twitter.com\/mamylona1\/statuses\/877821805766950912","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T09:33:22+00:00","author":{"name":"mamylona","image":"https:\/\/pbs.twimg.com\/profile_images\/691356827888525312\/UT1giEdl_normal.jpg","id_on_source":"mamylona1","tweeter_id":"4843178105","geo":{"lt":null,"ln":null},"followers":44},"tweet_id":"877821805766950912"},{"url":"http:\/\/twitter.com\/induspulmon\/statuses\/877874585940533248","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-22T13:03:06+00:00","author":{"name":"Dr.Raj: CriticalCare","url":"http:\/\/bit.ly\/carlorajmd","image":"https:\/\/pbs.twimg.com\/profile_images\/707060127438753793\/W6Pd1cE5_normal.jpg","description":"Facilitating the latest in #pulmonary & #criticalcare for our growing #MedEdcommunity. #USMLE\nCurated & Moderated by @CarloRajMD.","id_on_source":"induspulmon","tweeter_id":"705515439082774530","geo":{"lt":26.35869,"ln":-80.0831,"country":"US"},"followers":974},"tweet_id":"877874585940533248"},{"url":"http:\/\/twitter.com\/YorkNHSLibrary\/statuses\/877883787442401280","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-22T13:39:39+00:00","author":{"name":"York NHS Library","url":"https:\/\/www.yorkhospitals.nhs.uk\/our_services\/az_of_services\/library\/","image":"https:\/\/pbs.twimg.com\/profile_images\/799562814348214272\/bs5d7E44_normal.jpg","description":"The Library Service offers a fully integrated physical and virtual knowledge base. This account is monitored within staffed hours (9am - 5pm, Monday - Friday)","id_on_source":"YorkNHSLibrary","tweeter_id":"794563608910974977","geo":{"lt":null,"ln":null},"followers":125},"tweet_id":"877883787442401280"},{"url":"http:\/\/twitter.com\/juancaz17\/statuses\/877884133371936768","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T13:41:02+00:00","author":{"name":"Juan Carlos Londo\u00f1o","image":"https:\/\/pbs.twimg.com\/profile_images\/607567908550635520\/yT-soXHQ_normal.jpg","description":"Estudiante de Medicina, Amante de Dios y Persona dedicada a ayudar a los dem\u00e1s.","id_on_source":"juancaz17","tweeter_id":"2173221474","geo":{"lt":null,"ln":null},"followers":21},"tweet_id":"877884133371936768"},{"url":"http:\/\/twitter.com\/ichi1matsu\/statuses\/877885582768132096","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-22T13:46:47+00:00","author":{"name":"ichi matsumoto","image":"https:\/\/pbs.twimg.com\/profile_images\/2360484666\/picmix-262012-21514_normal.jpeg","description":"\u81ea\u8ee2\u8eca\u30ed\u30fc\u30c9\u30ec\u30fc\u30b9\u597d\u304d\u3001\u5730\u5143\u306a\u306e\u3067\u611b\u4e09\u30ec\u30fc\u30b7\u30f3\u30b0\u30b5\u30dd\u30fc\u30bf\u30fc\u3000A Community pharmacist at Aichi pref and holiday cyclist .Following UCI Asia tour because of Aisanracingteam supporter!!","id_on_source":"ichi1matsu","tweeter_id":"106564532","geo":{"lt":35.18147,"ln":136.90641,"country":"JP"},"followers":73},"tweet_id":"877885582768132096"},{"url":"http:\/\/twitter.com\/s_yeverino\/statuses\/877893860998864896","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T14:19:41+00:00","author":{"name":"Dr. Pedro Yeverino S","url":"http:\/\/medicasur.org.mx","image":"https:\/\/pbs.twimg.com\/profile_images\/540257044625100800\/0ahF2x2C_normal.jpeg","description":"M\u00e9dico Internista Jefe de Urgencias M\u00e9dica Sur. Bienvenido a La Trinchera: Quiero lo mejor de ti, lo quiero r\u00e1pido y lo quiero con una sonrisa. Twitts son mios","id_on_source":"s_yeverino","tweeter_id":"2901288383","geo":{"lt":19.42847,"ln":-99.12766,"country":"MX"},"followers":513},"tweet_id":"877893860998864896"},{"url":"http:\/\/twitter.com\/Saramirzaei\/statuses\/877912788856975361","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T15:34:54+00:00","author":{"name":"Sara Mirzaei","image":"https:\/\/pbs.twimg.com\/profile_images\/731636459434696704\/SyzuxQR6_normal.jpg","id_on_source":"Saramirzaei","tweeter_id":"29463447","geo":{"lt":null,"ln":null},"followers":62},"tweet_id":"877912788856975361"},{"url":"http:\/\/twitter.com\/JoseMartinConde\/statuses\/877941992021516289","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-22T17:30:56+00:00","author":{"name":"Jos\u00e9 Ant_Mart\u00ednConde","image":"https:\/\/pbs.twimg.com\/profile_images\/681104970972807169\/LRO0xZVU_normal.jpg","description":"Uno, a lo largo de la vida, se hace las mismas preguntas, Lo que va cambiando son las respuestas (Octavio Paz)","id_on_source":"JoseMartinConde","tweeter_id":"4621804305","geo":{"lt":null,"ln":null},"followers":109},"tweet_id":"877941992021516289"},{"url":"http:\/\/twitter.com\/bibliotecaemcs\/statuses\/877969849040777216","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-22T19:21:38+00:00","author":{"name":"BIBLIOTECA EMCS","url":"http:\/\/biblioteca.mty.itesm.mx","image":"https:\/\/pbs.twimg.com\/profile_images\/3148733515\/30aa0e280777ddc887082ac9f87a886b_normal.jpeg","description":"Biblioteca especializada en Medicina y Ciencias de la Salud.","id_on_source":"bibliotecaemcs","tweeter_id":"182492761","geo":{"lt":25.67506,"ln":-100.31846,"country":"MX"},"followers":1677},"tweet_id":"877969849040777216"},{"url":"http:\/\/twitter.com\/qgorgas\/statuses\/877975912599486464","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-22T19:45:44+00:00","author":{"name":"Maria Queralt Gorgas","image":"https:\/\/pbs.twimg.com\/profile_images\/506699397862658048\/MXK-ca4n_normal.png","description":"Farmac\u00e9utica hospitalaria","id_on_source":"qgorgas","tweeter_id":"2295351633","geo":{"lt":41.82046,"ln":1.86768,"country":"ES"},"followers":479},"tweet_id":"877975912599486464"},{"url":"http:\/\/twitter.com\/Kidedoc\/statuses\/878284835441307649","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-23T16:13:17+00:00","author":{"name":"Dr. Kevin Chan","image":"https:\/\/pbs.twimg.com\/profile_images\/451183160697438209\/3HkgXiCg_normal.jpeg","description":"Chief of Peds, Global Health doc, Wanderer, Fan of kids everywhere","id_on_source":"Kidedoc","tweeter_id":"2413749461","geo":{"lt":47.56494,"ln":-52.70931,"country":"CA"},"followers":271},"tweet_id":"878284835441307649"},{"url":"http:\/\/twitter.com\/MMJoseA1\/statuses\/878562546084716545","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-24T10:36:48+00:00","author":{"name":"Jos\u00e9 Antonio Morales","image":"https:\/\/pbs.twimg.com\/profile_images\/863411882316754944\/4pEieglJ_normal.jpg","description":"Clinical Pharmacist, phD - Hospital of Poniente. Professor at the University of Granada. In love with Investigation, Innovation and Clinical Trials","id_on_source":"MMJoseA1","tweeter_id":"863359194497470465","geo":{"lt":40,"ln":-4,"country":"ES"},"followers":259},"tweet_id":"878562546084716545"},{"url":"http:\/\/twitter.com\/AHC_Nurses\/statuses\/879399030211710978","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-26T18:00:41+00:00","author":{"name":"AHC Nurses","url":"http:\/\/Bestinnursing.org","image":"https:\/\/pbs.twimg.com\/profile_images\/822509837842059271\/U7noqyUi_normal.jpg","description":"The American Health Council Nurses - Providing the latest Nurse education news & information. Together, we strive to create a better healthcare system.","id_on_source":"AHC_Nurses","tweeter_id":"809142932271984641","geo":{"lt":40.82565,"ln":-73.20261,"country":"US"},"followers":17371},"tweet_id":"879399030211710978"},{"url":"http:\/\/twitter.com\/AHC_Doctors\/statuses\/879399031079923712","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-26T18:00:42+00:00","author":{"name":"AHC Doctors","url":"http:\/\/bestinmedicine.org","image":"https:\/\/pbs.twimg.com\/profile_images\/860127788774371328\/53xmCE7p_normal.jpg","description":"The American Health Council Doctors - Providing the latest medical & practice news & information. Together, we strive to create a better healthcare system.","id_on_source":"AHC_Doctors","tweeter_id":"809448599608324096","geo":{"lt":40.82565,"ln":-73.20261,"country":"US"},"followers":10212},"tweet_id":"879399031079923712"},{"url":"http:\/\/twitter.com\/AmerHealthCoun\/statuses\/879399033260961794","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-26T18:00:42+00:00","author":{"name":"AmericanHealthCounci","url":"http:\/\/www.americanhealthcouncil.org","image":"https:\/\/pbs.twimg.com\/profile_images\/755122008497750016\/ubgGqChQ_normal.jpg","description":"American Health Council \u2014 Comprised of leaders & contributors from all walks of healthcare. Together, we strive to create a better healthcare system. #AHC","id_on_source":"AmerHealthCoun","tweeter_id":"4924947179","geo":{"lt":40.82565,"ln":-73.20261,"country":"US"},"followers":15954},"tweet_id":"879399033260961794"},{"url":"http:\/\/twitter.com\/danirossmm\/statuses\/879796201352286217","license":"gnip","rt":["NEJM"],"citation_ids":[20391756],"posted_on":"2017-06-27T20:18:54+00:00","author":{"name":"Dani-Ross Monserrate","image":"https:\/\/pbs.twimg.com\/profile_images\/525967476740599808\/iRp4svWI_normal.jpeg","description":"MD Respiratory and Sleep Medicine, Clinical Trials, PFT, Asthma, COPD, TB","id_on_source":"danirossmm","tweeter_id":"634926828","geo":{"lt":null,"ln":null},"followers":209},"tweet_id":"879796201352286217"},{"url":"http:\/\/twitter.com\/LungOmics\/statuses\/880854539217149952","license":"gnip","citation_ids":[20391756],"posted_on":"2017-06-30T18:24:22+00:00","author":{"name":"LungOmics","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","description":"An automated account posting papers directly from pubmed, based on searches related to the 'omics of respiratory disease.","id_on_source":"LungOmics","tweeter_id":"781005050919391232","geo":{"lt":43.00035,"ln":-75.4999,"country":"US"},"followers":11},"tweet_id":"880854539217149952"},{"url":"http:\/\/twitter.com\/tomheston\/statuses\/881025209456775168","license":"gnip","citation_ids":[20391756],"posted_on":"2017-07-01T05:42:33+00:00","author":{"name":"Tom Heston","url":"http:\/\/tomheston.com","image":"https:\/\/pbs.twimg.com\/profile_images\/452650157050302464\/-kGG7sgd_normal.png","description":"I help people make wise health decisions. Theese are my medical newsfeed tweets. Follow @tomhestonmd for my personal tweets.","id_on_source":"tomheston","tweeter_id":"21013461","geo":{"lt":44.25,"ln":17.83333,"country":"BA"},"followers":83106},"tweet_id":"881025209456775168"},{"url":"http:\/\/twitter.com\/TKTarrant\/statuses\/881125135016701952","license":"gnip","citation_ids":[20391756],"posted_on":"2017-07-01T12:19:37+00:00","author":{"name":"Dr. Teresa Tarrant","url":"https:\/\/www.researchgate.net\/profile\/Teresa_Tarrant","image":"https:\/\/pbs.twimg.com\/profile_images\/792908549676347393\/XYYfC6td_normal.jpg","description":"Clinical immunologist in Rheumatology, Allergy, Aging, and Immune Deficiency","id_on_source":"TKTarrant","tweeter_id":"272472998","geo":{"lt":35.99403,"ln":-78.89862,"country":"US"},"followers":712},"tweet_id":"881125135016701952"},{"url":"http:\/\/twitter.com\/winder_gill\/statuses\/882774867719925760","license":"gnip","citation_ids":[20391756],"posted_on":"2017-07-06T01:35:04+00:00","author":{"name":"Dr. Winder Gill","image":"https:\/\/pbs.twimg.com\/profile_images\/530765692904439808\/pFAMESLW_normal.jpeg","description":"Western University; Division of Clinical Immunology & Allergy; Lifelong learner, inspired by those around me! Views are my own.","id_on_source":"winder_gill","tweeter_id":"2875332224","geo":{"lt":43.25011,"ln":-79.84963,"country":"CA"},"followers":455},"tweet_id":"882774867719925760"},{"url":"http:\/\/twitter.com\/atscommunity\/statuses\/892716931593142273","license":"gnip","citation_ids":[20391756],"posted_on":"2017-08-02T12:01:17+00:00","author":{"name":"American Thoracic","url":"http:\/\/www.thoracic.org","image":"https:\/\/pbs.twimg.com\/profile_images\/344513261572763798\/92463847ddc2462b8e42f4da947217cf_normal.jpeg","description":"We Help the World Breathe","id_on_source":"atscommunity","tweeter_id":"50076632","geo":{"lt":43.00035,"ln":-75.4999,"country":"US"},"followers":16079},"tweet_id":"892716931593142273"},{"url":"http:\/\/twitter.com\/pirinoes\/statuses\/892726844654366720","license":"gnip","rt":["atscommunity"],"citation_ids":[20391756],"posted_on":"2017-08-02T12:40:40+00:00","author":{"name":"Annie","image":"https:\/\/pbs.twimg.com\/profile_images\/711508515110543360\/ZDW3Gwen_normal.jpg","description":"Former market analyst & editor, patient safety advocate, preventive health; interested in translating research into practice, AI, DL, & NLP","id_on_source":"pirinoes","tweeter_id":"134613598","geo":{"lt":-27.46794,"ln":153.02809,"country":"AU"},"followers":516},"tweet_id":"892726844654366720"},{"url":"http:\/\/twitter.com\/negrita73bn\/statuses\/892734312105353216","license":"gnip","rt":["atscommunity"],"citation_ids":[20391756],"posted_on":"2017-08-02T13:10:20+00:00","author":{"name":"Ivonne Torres A.","image":"https:\/\/pbs.twimg.com\/profile_images\/906489945241608197\/16xN2Pvs_normal.jpg","description":"Doctora en Farmacolog\u00eda (ex becaria de SENACYT) Farmac\u00e9utica. Madre, hija y hermana, orgullosa de mi familia y pa\u00eds. Mujer de ciencias.@CienciaPTY -UP","id_on_source":"negrita73bn","tweeter_id":"626166984","geo":{"lt":8.9936,"ln":-79.51973,"country":"PA"},"followers":345},"tweet_id":"892734312105353216"},{"url":"http:\/\/twitter.com\/atscommunity\/statuses\/895676560237363200","license":"gnip","citation_ids":[20391756],"posted_on":"2017-08-10T16:01:47+00:00","author":{"name":"American Thoracic","url":"http:\/\/www.thoracic.org","image":"https:\/\/pbs.twimg.com\/profile_images\/344513261572763798\/92463847ddc2462b8e42f4da947217cf_normal.jpeg","description":"We Help the World Breathe","id_on_source":"atscommunity","tweeter_id":"50076632","geo":{"lt":43.00035,"ln":-75.4999,"country":"US"},"followers":16079},"tweet_id":"895676560237363200"},{"url":"http:\/\/twitter.com\/PasqualiniDario\/statuses\/895688710901182467","license":"gnip","rt":["atscommunity"],"citation_ids":[20391756],"posted_on":"2017-08-10T16:50:04+00:00","author":{"name":"Dario Pasqualini","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","id_on_source":"PasqualiniDario","tweeter_id":"873467362573529088","geo":{"lt":null,"ln":null},"followers":3},"tweet_id":"895688710901182467"},{"url":"http:\/\/twitter.com\/kawauso_srmsrnm\/statuses\/909425124683636737","license":"gnip","citation_ids":[20391756],"posted_on":"2017-09-17T14:33:40+00:00","author":{"name":"\u304b\u308f\u3046\u305d@\u77e5\u308b\u3082\u77e5\u3089\u306c\u3082","url":"http:\/\/shirumoshiranumo.blogspot.jp","image":"https:\/\/pbs.twimg.com\/profile_images\/756500377529294848\/JQrlLWGM_normal.jpg","description":"\u300c\u77e5\u308b\u3082\u77e5\u3089\u306c\u3082\u300d\u3068\u3044\u3046\u3001\u52c9\u5f37\u4f1a\u306e\u8a18\u9332\u30d6\u30ed\u30b0\u3092\u3084\u3063\u3066\u3044\u307e\u3059\u3002\u95a2\u897f\u306e\u4e00\u822c\u5e02\u4e2d\u75c5\u9662\u306e\u5185\u79d1\u7cfb\u533b\u5e2b\uff0810\u5e74\u76ee\u524d\u5f8c\uff09\u3067\u3059\u3002","id_on_source":"kawauso_srmsrnm","tweeter_id":"728589921179471873","geo":{"lt":34.81352,"ln":135.64914,"country":"JP"},"followers":62},"tweet_id":"909425124683636737"}],"googleplus":[{"url":"https:\/\/plus.google.com\/+JuanCarlosIvancevichMD\/posts\/bLrPm8uQCM7","license":"public","citation_ids":[20391756],"posted_on":"2017-05-22T19:47:54+00:00","summary":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 NEJM Original Article from The New England Journal of Medicine \u2014 Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1703501"},{"title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 http:\/\/ow.ly\/5Dko30cQdv9 #health...","url":"https:\/\/plus.google.com\/111494218731137257600\/posts\/Yja8tGK6duP","license":"public","citation_ids":[20391756],"posted_on":"2017-06-26T18:01:06+00:00","summary":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 http:\/\/ow.ly\/5Dko30cQdv9 #health... Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma \u2014 http:\/\/ow.ly\/5Dko30cQdv9 #health #asthma\ufeff Oral Glucocorticoid\u2013Sparing Effect of","author":{"name":"American Health Council","url":"https:\/\/plus.google.com\/111494218731137257600","image":"https:\/\/lh3.googleusercontent.com\/-2LXOWlHN3NQ\/AAAAAAAAAAI\/AAAAAAAABzg\/KidMkkD_G-Y\/photo.jpg?sz=50","id_on_source":"111494218731137257600"}}],"blogs":[{"title":"Richard Lehman\u2019s journal review\u201430 May 2017","url":"http:\/\/blogs.bmj.com\/bmj\/2017\/05\/30\/richard-lehmans-journal-review-30-may-2017\/","license":"public","citation_ids":[20489732,20386819,20295091,20366790,20366926,20391756,20413869,20412887,20387721,20396637,20372756,20373186,20432451,20491407,20463930,5631692,20427463],"posted_on":"2017-05-30T08:05:00+00:00","summary":"Richard Lehman reviews the latest research in the top medical journals\n\nNEJM&nbsp; 25 May 2017&nbsp; Vol 376\nAssisted dying in hospital\nAssisted dying has now been legalized in some form in five European countries (the Netherlands, Belgium, Switzerland, Ge","author":{"name":"Latest BMJ blogs","url":"http:\/\/blogs.bmj.com\/bmj","description":"Just another blogs.bmj.com weblog"}}],"wikipedia":[{"title":"Benralizumab","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=787312130#altmetric_citation_7888005e-3558-4c51-8807-7e69b212443d","license":"public","citation_ids":[20391756],"posted_on":"2017-06-24T17:48:14+00:00","summary":"Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016.","page_url":"http:\/\/en.wikipedia.org\/?curid=26799209","wiki_lang":"en","author":{"name":"Anypodetos","url":"http:\/\/en.wikipedia.org\/wiki\/User:Anypodetos"}}]}}